BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264-269. [PMID: 20018759 DOI: 10.1073/pnas.0907904107] [Cited by in Crossref: 508] [Cited by in F6Publishing: 495] [Article Influence: 42.3] [Reference Citation Analysis]
Number Citing Articles
1 de Conti A, Ortega JF, Tryndyak V, Dreval K, Moreno FS, Rusyn I, Beland FA, Pogribny IP. MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis. Oncotarget. 2017;8:88517-88528. [PMID: 29179453 DOI: 10.18632/oncotarget.19774] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
2 Javid H, Soltani A, Mohammadi F, Hashemy SI. Emerging roles of microRNAs in regulating the mTOR signaling pathway during tumorigenesis. J Cell Biochem 2019;120:10874-83. [DOI: 10.1002/jcb.28401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, Baldwin AS, Fisher PB, Sarkar D. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem. 2012;287:13952-13958. [PMID: 22396537 DOI: 10.1074/jbc.m111.321646] [Cited by in Crossref: 91] [Cited by in F6Publishing: 59] [Article Influence: 10.1] [Reference Citation Analysis]
4 Ali HEA, Abdel Hameed R, Effat H, Ahmed EK, Atef AA, Sharawi SK, Ali M, Abd Elmageed ZY, Abdel Wahab AH. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41:e51-e62. [PMID: 28750770 DOI: 10.1016/j.clinre.2017.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
5 Han H, Du Y, Zhao W, Li S, Chen D, Zhang J, Liu J, Suo Z, Bian X, Xing B, Zhang Z. PBX3 is targeted by multiple miRNAs and is essential for liver tumour-initiating cells. Nat Commun. 2015;6:8271. [PMID: 26420065 DOI: 10.1038/ncomms9271] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
6 Seong M, Lee J, Kang H. Hypoxia-induced regulation of mTOR signaling by miR-7 targeting REDD1. J Cell Biochem 2019;120:4523-32. [PMID: 30302791 DOI: 10.1002/jcb.27740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Liu W, Yeh S, Chen P. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2011;1809:678-85. [DOI: 10.1016/j.bbagrm.2011.04.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
8 Rojas E, Martinez-Pacheco M, Rodriguez-Sastre MA, Ramos-Espinosa P, Valverde M. Post-transcriptional regulation of Rad51c by miR-222 contributes cellular transformation. PLoS One 2020;15:e0221681. [PMID: 31923208 DOI: 10.1371/journal.pone.0221681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Li S, Liang Y, Wu M, Wang X, Fu H, Chen Y, Wang Z. The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 2013;13:30. [PMID: 23537100 DOI: 10.1186/1475-2867-13-30] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
10 Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 2012;32:772-782. [PMID: 22429613 DOI: 10.1111/j.1478-3231.2012.02795.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
11 Thibault PA, Wilson JA. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res 2013;75:48-59. [PMID: 23541631 DOI: 10.1016/j.phrs.2013.03.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
12 Albulescu R, Neagu M, Albulescu L, Tanase C. Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert Rev Mol Diagn. 2011;11:101-120. [PMID: 21171925 DOI: 10.1586/erm.10.106] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
13 Fatima S, Lee NP, Luk JM. Dickkopfs and Wnt/β-catenin signalling in liver cancer. World J Clin Oncol 2011;2:311-25. [PMID: 21876852 DOI: 10.5306/wjco.v2.i8.311] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
14 Qian F, Wang J, Wang Y, Gao Q, Yan W, Lin Y, Shen L, Xie Y, Jiang X, Shen B. MiR-378a-3p as a putative biomarker for hepatocellular carcinoma diagnosis and prognosis: Computational screening with experimental validation. Clin Transl Med 2021;11:e307. [PMID: 33634974 DOI: 10.1002/ctm2.307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kawano M, Tanaka K, Itonaga I, Ikeda S, Iwasaki T, Tsumura H. microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells. J Exp Clin Cancer Res 2015;34:76. [PMID: 26243299 DOI: 10.1186/s13046-015-0192-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
16 Lyu X, Fang W, Cai L, Zheng H, Ye Y, Zhang L, Li J, Peng H, Cho WC, Wang E, Marincola FM, Yao K, Cai H, Li J, Li X. TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer 2014;13:51. [PMID: 24606633 DOI: 10.1186/1476-4598-13-51] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 8.6] [Reference Citation Analysis]
17 Brase JC, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9:306. [PMID: 21110877 DOI: 10.1186/1476-4598-9-306] [Cited by in Crossref: 281] [Cited by in F6Publishing: 257] [Article Influence: 25.5] [Reference Citation Analysis]
18 Gibbs KD Jr, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP, Majeti R. Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. Blood 2011;117:4226-33. [PMID: 21357764 DOI: 10.1182/blood-2010-07-298232] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
19 Greene CM, Varley RB, Lawless MW. MicroRNAs and liver cancer associated with iron overload: therapeutic targets unravelled. World J Gastroenterol. 2013;19:5212-5226. [PMID: 23983424 DOI: 10.3748/wjg.v19.i32.5212] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
20 Liu W, Hu K, Zhang F, Lu S, Chen R, Ren Z, Yin X. The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis. Int J Biol Markers 2021;36:17246008211032689. [PMID: 34374576 DOI: 10.1177/17246008211032689] [Reference Citation Analysis]
21 Franzoni S, Vezzelli A, Turtoro A, Solazzo L, Greco A, Tassone P, Di Martino M, Breda M. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2018;150:300-7. [DOI: 10.1016/j.jpba.2017.12.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
22 Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y, Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, Wang N, Ye C, Zhao C, Liu Y, Fan Q, Zhang CY, Sang J, Zen K, Chen X. miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer. Sci Rep 2016;6:37421. [PMID: 27857177 DOI: 10.1038/srep37421] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 11.2] [Reference Citation Analysis]
23 Yang N, Ekanem NR, Sakyi CA, Ray SD. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics. Adv Drug Deliv Rev. 2015;81:62-74. [PMID: 25450260 DOI: 10.1016/j.addr.2014.10.029] [Cited by in Crossref: 108] [Cited by in F6Publishing: 109] [Article Influence: 15.4] [Reference Citation Analysis]
24 Roscigno G, Quintavalle C, Donnarumma E, Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M, Romano G, Thomas R, Cortino G, Gaggianesi M, Esteller M, Croce CM, Condorelli G. MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget 2016;7:580-92. [PMID: 26556862 DOI: 10.18632/oncotarget.5979] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 12.0] [Reference Citation Analysis]
25 Zuntini M, Salvatore M, Pedrini E, Parra A, Sgariglia F, Magrelli A, Taruscio D, Sangiorgi L. MicroRNA profiling of multiple osteochondromas: identification of disease-specific and normal cartilage signatures. Clin Genet 2010;78:507-16. [PMID: 20662852 DOI: 10.1111/j.1399-0004.2010.01490.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
26 Corvalan AH. Early diagnosis of hepatocellular carcinoma by microRNAs: shining a light from the genome's "dark matter". Dig Dis Sci 2012;57:2737-9. [PMID: 23014845 DOI: 10.1007/s10620-012-2384-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
27 Mizuguchi Y, Takizawa T, Uchida E. Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. World J Hepatol. 2015;7:696-702. [PMID: 25866606 DOI: 10.4254/wjh.v7.i4.696] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
28 Li QJ, Zhou L, Yang F, Wang GX, Zheng H, Wang DS, He Y, Dou KF. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumour Biol. 2012;33:1455-1465. [PMID: 22528944 DOI: 10.1007/s13277-012-0396-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 8.1] [Reference Citation Analysis]
29 Rong M, Chen G, Dang Y. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer. 2013;13:21. [PMID: 23320393 DOI: 10.1186/1471-2407-13-21] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 9.6] [Reference Citation Analysis]
30 Agostini M, Knight RA. miR-34: from bench to bedside. Oncotarget 2014;5:872-81. [PMID: 24657911 DOI: 10.18632/oncotarget.1825] [Cited by in Crossref: 160] [Cited by in F6Publishing: 161] [Article Influence: 26.7] [Reference Citation Analysis]
31 Morishita A, Masaki T. miRNA in hepatocellular carcinoma. Hepatol Res. 2015;45:128-141. [PMID: 25040738 DOI: 10.1111/hepr.12386] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
32 Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010;53:568-77. [PMID: 20646772 DOI: 10.1016/j.jhep.2010.05.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
33 Li G, Ren S, Su Z, Liu C, Deng T, Huang D, Tian Y, Qiu Y, Liu Y. Increased expression of miR-93 is associated with poor prognosis in head and neck squamous cell carcinoma. Tumour Biol. 2015;36:3949-3956. [PMID: 25578493 DOI: 10.1007/s13277-015-3038-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
34 Li J, Yan Y, Ang L, Li X, Liu C, Sun B, Lin X, Peng Z, Zhang X, Zhang Q, Wu H, Zhao M, Su C. Extracellular vesicles-derived OncomiRs mediate communication between cancer cells and cancer-associated hepatic stellate cells in hepatocellular carcinoma microenvironment. Carcinogenesis 2020;41:223-34. [PMID: 31140556 DOI: 10.1093/carcin/bgz096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
35 Yim SY, Lee J. The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma. J Liver Cancer 2019;19:97-107. [DOI: 10.17998/jlc.19.2.97] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Yin Z, Xu M, Li P. miRNA-221 acts as an oncogenic role by directly targeting TIMP2 in non-small-cell lung carcinoma. Gene 2017;620:46-53. [PMID: 28392366 DOI: 10.1016/j.gene.2017.04.007] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
37 Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R, Piva R. Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. BMC Cancer. 2012;12:445. [PMID: 23031797 DOI: 10.1186/1471-2407-12-445] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
38 Munker R, Calin GA. MicroRNA profiling in cancer. Clin Sci (Lond). 2011;121:141-158. [PMID: 21526983 DOI: 10.1042/CS20110005] [Cited by in Crossref: 115] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
39 Pontes TB, Moreira-Nunes Cde F, Maués JH, Lamarão LM, de Lemos JA, Montenegro RC, Burbano RM. The miRNA Profile of Platelets Stored in a Blood Bank and Its Relation to Cellular Damage from Storage. PLoS One 2015;10:e0129399. [PMID: 26121269 DOI: 10.1371/journal.pone.0129399] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
40 Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, Huang W. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010;52:2148-57. [PMID: 20979124 DOI: 10.1002/hep.23915] [Cited by in Crossref: 140] [Cited by in F6Publishing: 134] [Article Influence: 12.7] [Reference Citation Analysis]
41 Sohn W, Kim J, Kang SH, Yang SR, Cho JY, Cho HC, Shim SG, Paik YH. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med. 2015;47:e184. [PMID: 26380927 DOI: 10.1038/emm.2015.68] [Cited by in Crossref: 205] [Cited by in F6Publishing: 198] [Article Influence: 34.2] [Reference Citation Analysis]
42 Li Y, Di C, Li W, Cai W, Tan X, Xu L, Yang L, Lou G, Yan Y. Oncomirs miRNA-221/222 and Tumor Suppressors miRNA-199a/195 Are Crucial miRNAs in Liver Cancer: A Systematic Analysis. Dig Dis Sci 2016;61:2315-27. [PMID: 27156077 DOI: 10.1007/s10620-016-4156-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
43 Motawi TMK, Sadik NAH, Shaker OG, Ghaleb MH. Elevated serum microRNA-122/222 levels are potential diagnostic biomarkers in Egyptian patients with chronic hepatitis C but not hepatic cancer. Tumor Biol 2016;37:9865-74. [DOI: 10.1007/s13277-016-4884-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
44 El Tayebi HM, Waly AA, Assal RA, Hosny KA, Esmat G, Abdelaziz AI. Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncol Lett. 2015;10:3206-3212. [PMID: 26722313 DOI: 10.3892/ol.2015.3725] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
45 Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2016; Nov 23. [Epub ahead of print]. [PMID: 27889327 DOI: 10.1016/j.mam.2016.11.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 11.6] [Reference Citation Analysis]
46 Maeda Y, Farina NH, Matzelle MM, Fanning PJ, Lian JB, Gravallese EM. Synovium-Derived MicroRNAs Regulate Bone Pathways in Rheumatoid Arthritis. J Bone Miner Res 2017;32:461-72. [PMID: 27676131 DOI: 10.1002/jbmr.3005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
47 Chen Z, Xiang B, Qi L, Zhu S, Li L. miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase. Cancer Biol Ther 2020;21:915-26. [PMID: 33023393 DOI: 10.1080/15384047.2020.1806642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542-552. [PMID: 23689081 DOI: 10.1038/nrgastro.2013.87] [Cited by in Crossref: 367] [Cited by in F6Publishing: 339] [Article Influence: 45.9] [Reference Citation Analysis]
49 Dey N, Ghosh-Choudhury N, Kasinath BS, Choudhury GG. TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One 2012;7:e42316. [PMID: 22879939 DOI: 10.1371/journal.pone.0042316] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 9.6] [Reference Citation Analysis]
50 Shen X, Xue Y, Cong H, Wang X, Ju S. Dysregulation of serum microRNA-574-3p and its clinical significance in hepatocellular carcinoma. Ann Clin Biochem 2018;55:478-84. [PMID: 29065698 DOI: 10.1177/0004563217741908] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
51 Li J, Li P, Chen T, Gao G, Chen X, Du Y, Zhang R, Yang R, Zhao W, Dun S, Gao F, Zhang G. Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol 2015;36:685-92. [PMID: 25286764 DOI: 10.1007/s13277-014-2698-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
52 Waters PS, McDermott AM, Wall D, Heneghan HM, Miller N, Newell J, Kerin MJ, Dwyer RM. Relationship between circulating and tissue microRNAs in a murine model of breast cancer. PLoS One. 2012;7:e50459. [PMID: 23226290 DOI: 10.1371/journal.pone.0050459] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
53 Zekri AN, El-Sisi ER, Youssef ASE, Kamel MM, Nassar A, Ahmed OS, El Kassas M, Barakat AB, Abd El-Motaleb AI, Bahnassy AA. MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection. PLoS One 2018;13:e0193709. [PMID: 29534065 DOI: 10.1371/journal.pone.0193709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
54 Corsten MF, Heggermont W, Papageorgiou A, Deckx S, Tijsma A, Verhesen W, van Leeuwen R, Carai P, Thibaut H, Custers K, Summer G, Hazebroek M, Verheyen F, Neyts J, Schroen B, Heymans S. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis. European Heart Journal 2015;36:2909-19. [DOI: 10.1093/eurheartj/ehv321] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 9.3] [Reference Citation Analysis]
55 Chen Q, Zhou Y, Richards AM, Wang P. Up-regulation of miRNA-221 inhibits hypoxia/reoxygenation-induced autophagy through the DDIT4/mTORC1 and Tp53inp1/p62 pathways. Biochemical and Biophysical Research Communications 2016;474:168-74. [DOI: 10.1016/j.bbrc.2016.04.090] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
56 Lewis JM, Heineck DP, Heller MJ. Detecting cancer biomarkers in blood: challenges for new molecular diagnostic and point-of-care tests using cell-free nucleic acids. Expert Rev Mol Diagn 2015;15:1187-200. [PMID: 26189641 DOI: 10.1586/14737159.2015.1069709] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
57 Canal M, Romaní-Aumedes J, Martín-Flores N, Pérez-Fernández V, Malagelada C. RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders. Front Cell Neurosci 2014;8:313. [PMID: 25324725 DOI: 10.3389/fncel.2014.00313] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
58 Zhang H, Xing AY, Ma RR, Wang YW, Liu YH, Gao P. Diagnostic value of miRNA-96-5p/3p in dysplastic nodules and well-differentiated small hepatocellular carcinoma. Hepatol Res 2016;46:784-93. [PMID: 26609665 DOI: 10.1111/hepr.12628] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
59 Chen B, She S, Li D, Liu Z, Yang X, Zeng Z, Liu F. Role of miR-19a targeting TNF-α in mediating ulcerative colitis. Scand J Gastroenterol. 2013;48:815-824. [PMID: 23795660 DOI: 10.3109/00365521.2013.800991] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
60 Poma P, Labbozzetta M, Vivona N, Porcasi R, D'alessandro N, Notarbartolo M. Analysis of Possible Mechanisms Accounting for Raf-1 Kinase Inhibitor Protein Downregulation in Hepatocellular Carcinoma. OMICS: A Journal of Integrative Biology 2012;16:579-88. [DOI: 10.1089/omi.2012.0048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
61 Agostini M, Ganini C, Candi E, Melino G. The role of noncoding RNAs in epithelial cancer. Cell Death Discov 2020;6:13. [PMID: 32194993 DOI: 10.1038/s41420-020-0247-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
62 Lisse TS, Liu T, Irmler M, Beckers J, Chen H, Adams JS, Hewison M. Gene targeting by the vitamin D response element binding protein reveals a role for vitamin D in osteoblast mTOR signaling. FASEB J 2011;25:937-47. [PMID: 21123297 DOI: 10.1096/fj.10-172577] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 7.0] [Reference Citation Analysis]
63 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
64 Alqurashi N, Hashimi SM, Alowaidi F, Ivanovski S, Farag A, Wei MQ. miR-496, miR-1185, miR-654, miR-3183 and miR-495 are downregulated in colorectal cancer cells and have putative roles in the mTOR pathway. Oncol Lett 2019;18:1657-68. [PMID: 31423233 DOI: 10.3892/ol.2019.10508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
65 An F, Olaru AV, Mezey E, Xie Q, Li L, Piontek KB, Selaru FM. MicroRNA-224 Induces G1/S Checkpoint Release in Liver Cancer. J Clin Med 2015;4:1713-28. [PMID: 26343737 DOI: 10.3390/jcm4091713] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
66 Saito Y, Suzuki H, Matsuura M, Sato A, Kasai Y, Yamada K, Saito H, Hibi T. MicroRNAs in Hepatobiliary and Pancreatic Cancers. Front Genet. 2011;2:66. [PMID: 22303361 DOI: 10.3389/fgene.2011.00066] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
67 Turato C, Simonato D, Quarta S, Gatta A, Pontisso P. MicroRNAs and SerpinB3 in hepatocellular carcinoma. Life Sci. 2014;100:9-17. [PMID: 24496037 DOI: 10.1016/j.lfs.2014.01.073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
68 Lin L, Lu B, Yu J, Liu W, Zhou A. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage. Clin Res Hepatol Gastroenterol. 2016;40:397-404. [PMID: 26724963 DOI: 10.1016/j.clinre.2015.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
69 Menghini R, Federici M. MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver. EBioMedicine 2018;37:7-8. [PMID: 30344123 DOI: 10.1016/j.ebiom.2018.10.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
70 Gougelet A, Sartor C, Bachelot L, Godard C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B, Perret C, Colnot S. Antitumour activity of an inhibitor of miR-34a in liver cancer with β-catenin-mutations. Gut 2016;65:1024-34. [PMID: 25792709 DOI: 10.1136/gutjnl-2014-308969] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
71 Swellam M, Zahran RFK, Abo El-Sadat Taha H, El-Khazragy N, Abdel-Malak C. Role of some circulating MiRNAs on breast cancer diagnosis. Arch Physiol Biochem 2019;125:456-64. [PMID: 29925280 DOI: 10.1080/13813455.2018.1482355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
72 Shen J, Wang Q, Gurvich I, Remotti H, Santella RM. Evaluating normalization approaches for the better identification of aberrant microRNAs associated with hepatocellular carcinoma. Hepatoma Res. 2016;2:305-315. [PMID: 28393113 DOI: 10.20517/2394-5079.2016.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
73 Xu T, Liu X, Han L, Shen H, Liu L, Shu Y. Up-regulation of miR-9 expression as a poor prognostic biomarker in patients with non-small cell lung cancer. Clin Transl Oncol 2014;16:469-75. [DOI: 10.1007/s12094-013-1106-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
74 Sharma AD, Narain N, Händel EM, Iken M, Singhal N, Cathomen T, Manns MP, Schöler HR, Ott M, Cantz T. MicroRNA-221 regulates FAS-induced fulminant liver failure. Hepatology. 2011;53:1651-1661. [PMID: 21400558 DOI: 10.1002/hep.24243] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
75 Hung CH, Hu TH, Lu SN, Kuo FY, Chen CH, Wang JH, Huang CM, Lee CM, Lin CY, Yen YH, Chiu YC. Circulating microRNAs as biomarkers for diagnosis of early hepatocellular carcinoma associated with hepatitis B virus. Int J Cancer. 2016;138:714-720. [PMID: 26264553 DOI: 10.1002/ijc.29802] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
76 Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P. Mir-221/222 are promising targets for innovative anticancer therapy. Expert Opin Ther Targets 2016;20:1099-108. [PMID: 26959615 DOI: 10.1517/14728222.2016.1164693] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
77 Chen B, Liao Z, Qi Y, Zhang H, Su C, Liang H, Zhang B, Chen X. miR-631 Inhibits Intrahepatic Metastasis of Hepatocellular Carcinoma by Targeting PTPRE. Front Oncol 2020;10:565266. [PMID: 33344226 DOI: 10.3389/fonc.2020.565266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
78 Zhou N, Wu J, Wang X, Sun Z, Han Q, Zhao L. Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. Tumour Biol. 2016;37:2145-2152. [PMID: 26349912 DOI: 10.1007/s13277-015-3841-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
79 Plissonnier ML, Herzog K, Levrero M, Zeisel MB. Non-Coding RNAs and Hepatitis C Virus-Induced Hepatocellular Carcinoma. Viruses. 2018;10. [PMID: 30380697 DOI: 10.3390/v10110591] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
80 Ma X, Shi W, Peng L, Qin X, Hui Y. MiR-96 enhances cellular proliferation and tumorigenicity of human cervical carcinoma cells through PTPN9. Saudi J Biol Sci 2018;25:863-7. [PMID: 30108433 DOI: 10.1016/j.sjbs.2017.10.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
81 Fernandez N, Cordiner RA, Young RS, Hug N, Macias S, Cáceres JF. Genetic variation and RNA structure regulate microRNA biogenesis. Nat Commun 2017;8:15114. [PMID: 28466845 DOI: 10.1038/ncomms15114] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
82 Bencivenga D, Caldarelli I, Stampone E, Mancini FP, Balestrieri ML, Della Ragione F, Borriello A. p27 Kip1 and human cancers: A reappraisal of a still enigmatic protein. Cancer Letters 2017;403:354-65. [DOI: 10.1016/j.canlet.2017.06.031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
83 Elkhenany H, Shekshek A, Abdel-Daim M, El-Badri N. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Adv Exp Med Biol 2020;1237:97-119. [PMID: 31728916 DOI: 10.1007/5584_2019_441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
84 Su A, He S, Tian B, Hu W, Zhang Z. MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. PLoS One. 2013;8:e71309. [PMID: 23967190 DOI: 10.1371/journal.pone.0071309] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
85 Lyra-González I, Flores-Fong LE, González-García I, Medina-Preciado D, Armendáriz-Borunda J. MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine. World J Hepatol 2015;7:1530-40. [PMID: 26085912 DOI: 10.4254/wjh.v7.i11.1530] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
86 Motawi TM, Sadik NA, Shaker OG, El Masry MR, Mohareb F. Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women. Gene 2016;590:210-9. [PMID: 26827795 DOI: 10.1016/j.gene.2016.01.042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
87 Li L, Liu Y, Guo Y, Liu B, Zhao Y, Li P, Song F, Zheng H, Yu J, Song T, Niu R, Li Q, Wang XW, Zhang W, Chen K. Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology. 2015;61:574-584. [PMID: 25271001 DOI: 10.1002/hep.27543] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 9.8] [Reference Citation Analysis]
88 Jin Y, Wong YS, Goh BKP, Chan CY, Cheow PC, Chow PKH, Lim TKH, Goh GBB, Krishnamoorthy TL, Kumar R, Ng TP, Chong SS, Tan HH, Chung AYF, Ooi LLPJ, Chang JPE, Tan CK, Lee CGL. Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma. Sci Rep. 2019;9:10464. [PMID: 31320713 DOI: 10.1038/s41598-019-46872-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 18.0] [Reference Citation Analysis]
89 Yang H, Li TW, Peng J, Tang X, Ko KS, Xia M, Aller MA. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology 2011; 141: 378-388, 388.e1-388. e4. [PMID: 21440549 DOI: 10.1053/j.gastro.2011.03.044] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 8.0] [Reference Citation Analysis]
90 Li T, Zhang G, Wang L, Li S, Xu X, Gao Y. Defects in mTORC1 Network and mTORC1-STAT3 Pathway Crosstalk Contributes to Non-inflammatory Hepatocellular Carcinoma. Front Cell Dev Biol. 2020;8:225. [PMID: 32363190 DOI: 10.3389/fcell.2020.00225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
91 Shaker O, Alhelf M, Morcos G, Elsharkawy A. miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. Infection, Genetics and Evolution 2017;51:173-81. [DOI: 10.1016/j.meegid.2017.03.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
92 Li F, Wang F, Zhu C, Wei Q, Zhang T, Zhou YL. miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker. Int J Nanomedicine 2018;13:2295-307. [PMID: 29713162 DOI: 10.2147/IJN.S157805] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
93 García-Gutiérrez L, Delgado MD, León J. MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes (Basel) 2019;10:E244. [PMID: 30909496 DOI: 10.3390/genes10030244] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 24.5] [Reference Citation Analysis]
94 Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D, Luo R. MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 2012;586:884-891. [PMID: 22449976 DOI: 10.1016/j.febslet.2012.02.017] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 8.7] [Reference Citation Analysis]
95 Chu R, Mo G, Duan Z, Huang M, Chang J, Li X, Liu P. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal. 2014;12:45. [PMID: 25012758 DOI: 10.1186/s12964-014-0045-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
96 Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci. 2012;57:2910-2916. [PMID: 22865399 DOI: 10.1007/s10620-012-2317-y] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
97 Fan R, Xiao C, Wan X, Cha W, Miao Y, Zhou Y, Qin C, Cui T, Su F, Shan X. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol 2019;16:707-18. [PMID: 30900502 DOI: 10.1080/15476286.2019.1593094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
98 Gomez-Cambronero J. Lack of effective translational regulation of PLD expression and exosome biogenesis in triple-negative breast cancer cells. Cancer Metastasis Rev 2018;37:491-507. [PMID: 30091053 DOI: 10.1007/s10555-018-9753-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
99 Luo C, Yin D, Zhan H, Borjigin U, Li C, Zhou Z, Hu Z, Wang P, Sun Q, Fan J, Zhou J, Wang X, Zhou S, Huang X. microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A. Cell Death Dis 2018;9:535. [PMID: 29749382 DOI: 10.1038/s41419-018-0577-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
100 Ding L, Wang R, Shen D, Cheng S, Wang H, Lu Z, Zheng Q, Wang L, Xia L, Li G. Role of noncoding RNA in drug resistance of prostate cancer. Cell Death Dis 2021;12:590. [PMID: 34103477 DOI: 10.1038/s41419-021-03854-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
101 Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, Ni Chonghaile T, Johncilla ME, Tai YT, Cheng JQ, Letai A, Munshi NC, Anderson KC, Carrasco RD. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res 2015;75:4384-97. [PMID: 26249174 DOI: 10.1158/0008-5472.CAN-15-0457] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 8.7] [Reference Citation Analysis]
102 He S, Zhang DC, Wei C. MicroRNAs as biomarkers for hepatocellular carcinoma diagnosis and prognosis. Clin Res Hepatol Gastroenterol. 2015;39:426-434. [PMID: 25746139 DOI: 10.1016/j.clinre.2015.01.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
103 Cai P, Piao X, Liu S, Hou N, Wang H, Chen Q. MicroRNA-gene expression network in murine liver during Schistosoma japonicum infection. PLoS One 2013;8:e67037. [PMID: 23825609 DOI: 10.1371/journal.pone.0067037] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
104 Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, Park WS, Lee JY, Nam SW. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013;335:455-462. [PMID: 23499894 DOI: 10.1016/j.canlet.2013.03.003] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 10.0] [Reference Citation Analysis]
105 Catuogno S, Rienzo A, Di Vito A, Esposito CL, de Franciscis V. Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates. J Control Release 2015;210:147-59. [PMID: 25998051 DOI: 10.1016/j.jconrel.2015.05.276] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
106 Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma. Hepatol Res 2016;46:89-99. [PMID: 26284466 DOI: 10.1111/hepr.12571] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
107 Kumar A. MicroRNA in HCV infection and liver cancer. Biochim Biophys Acta 2011;1809:694-9. [PMID: 21821155 DOI: 10.1016/j.bbagrm.2011.07.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
108 Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng IO. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology. 2011;140:322-331. [PMID: 20951699 DOI: 10.1053/j.gastro.2010.10.006] [Cited by in Crossref: 213] [Cited by in F6Publishing: 216] [Article Influence: 19.4] [Reference Citation Analysis]
109 Lee J, Choi K, Moon SU, Kim S. Theragnosis-based combined cancer therapy using doxorubicin-conjugated microRNA-221 molecular beacon. Biomaterials 2016;74:109-18. [DOI: 10.1016/j.biomaterials.2015.09.036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
110 Markovic J, Sharma AD, Balakrishnan A. MicroRNA-221: A Fine Tuner and Potential Biomarker of Chronic Liver Injury. Cells 2020;9:E1767. [PMID: 32717951 DOI: 10.3390/cells9081767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
111 Riazalhosseini B, Mohamed R, Apalasamy YD, Langmia IM, Mohamed Z. Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B. Rev Soc Bras Med Trop 2017;50:161-6. [PMID: 28562750 DOI: 10.1590/0037-8682-0416-2016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
112 Liang GF, Zhu YL, Sun B, Hu FH, Tian T, Li SC, Xiao ZD. PLGA-based gene delivering nanoparticle enhance suppression effect of miRNA in HePG2 cells. Nanoscale Res Lett 2011;6:447. [PMID: 21749688 DOI: 10.1186/1556-276X-6-447] [Cited by in Crossref: 58] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
113 Braun J, Hüttelmaier S. Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res 2011;4 Suppl 1:S1. [PMID: 21835047 DOI: 10.1186/1756-6614-4-S1-S1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
114 Santoro MM, Nicoli S. miRNAs in endothelial cell signaling: the endomiRNAs. Exp Cell Res 2013;319:1324-30. [PMID: 23262024 DOI: 10.1016/j.yexcr.2012.12.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
115 Koufaris C, Wright J, Currie RA, Gooderham NJ. Hepatic microRNA profiles offer predictive and mechanistic insights after exposure to genotoxic and epigenetic hepatocarcinogens. Toxicol Sci. 2012;128:532-543. [PMID: 22584684 DOI: 10.1093/toxsci/kfs170] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
116 Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167-1178. [PMID: 24039437 DOI: 10.2147/ott.s36161] [Cited by in Crossref: 19] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
117 Cochrane DR, Cittelly DM, Richer JK. Steroid receptors and microRNAs: relationships revealed. Steroids 2011;76:1-10. [PMID: 21093468 DOI: 10.1016/j.steroids.2010.11.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
118 Hatziapostolou M, Polytarchou C, Iliopoulos D. miRNAs link metabolic reprogramming to oncogenesis. Trends Endocrinol Metab 2013;24:361-73. [PMID: 23602813 DOI: 10.1016/j.tem.2013.03.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
119 Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci 2020;21:E8362. [PMID: 33171811 DOI: 10.3390/ijms21218362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
120 Jadhav V, Hackl M, Bort JA, Wieser M, Harreither E, Kunert R, Borth N, Grillari J. A screening method to assess biological effects of microRNA overexpression in Chinese hamster ovary cells. Biotechnol Bioeng 2012;109:1376-85. [PMID: 22407745 DOI: 10.1002/bit.24490] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
121 Gao C, Wei J, Tang T, Huang Z. Role of microRNA-33a in malignant cells. Oncol Lett 2020;20:2537-56. [PMID: 32782572 DOI: 10.3892/ol.2020.11835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
122 Chiu LY, Kishnani PS, Chuang TP, Tang CY, Liu CY, Bali D, Koeberl D, Austin S, Boyette K, Weinstein DA. Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers. J Gastroenterol. 2014;49:1274-1284. [PMID: 24129885 DOI: 10.1007/s00535-013-0890-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
123 Tian XF, Ji FJ, Zang HL, Cao H. Activation of the miR-34a/SIRT1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis via Inducing Apoptosis in Hepatocytes but Not in HSCs. PLoS One. 2016;11:e0158657. [PMID: 27387128 DOI: 10.1371/journal.pone.0158657] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
124 Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol. 2012;56:855-861. [PMID: 22178270 DOI: 10.1016/j.jhep.2011.11.017] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
125 Jiang X, Jiang L, Shan A, Su Y, Cheng Y, Song D, Ji H, Ning G, Wang W, Cao Y. Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice. EBioMedicine 2018;37:307-21. [PMID: 30316865 DOI: 10.1016/j.ebiom.2018.09.051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
126 Yang QE, Racicot KE, Kaucher AV, Oatley MJ, Oatley JM. MicroRNAs 221 and 222 regulate the undifferentiated state in mammalian male germ cells. Development 2013;140:280-90. [PMID: 23221369 DOI: 10.1242/dev.087403] [Cited by in Crossref: 112] [Cited by in F6Publishing: 92] [Article Influence: 12.4] [Reference Citation Analysis]
127 Sehgal M, Zeremski M, Talal AH, Ginwala R, Elrod E, Grakoui A, Li QG, Philip R, Khan ZK, Jain P. IFN-α-Induced Downregulation of miR-221 in Dendritic Cells: Implications for HCV Pathogenesis and Treatment. J Interferon Cytokine Res 2015;35:698-709. [PMID: 26090579 DOI: 10.1089/jir.2014.0211] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
128 Gougelet A, Colnot S. MicroRNA-feedback loop as a key modulator of liver tumorigenesis and inflammation. World J Gastroenterol. 2013;19:440-444. [PMID: 23382622 DOI: 10.3748/wjg.v19.i4.440] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
129 Wang R, Hu X, Liu X, Bai L, Gu J, Li Q. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis. PLoS One 2021;16:e0249881. [PMID: 33861762 DOI: 10.1371/journal.pone.0249881] [Reference Citation Analysis]
130 Wang Q, Gao Y, Ji X, Qi X, Qin L, Gao H, Wang Y, Wang X. Differential expression of microRNAs in avian leukosis virus subgroup J-induced tumors. Vet Microbiol 2013;162:232-8. [PMID: 23157947 DOI: 10.1016/j.vetmic.2012.10.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
131 Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology. 2011;53:2112-2121. [PMID: 21433041 DOI: 10.1002/hep.24313] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
132 Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids 2019;14:239-50. [PMID: 30641476 DOI: 10.1016/j.omtn.2018.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
133 Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342:223-230. [PMID: 22306342 DOI: 10.1016/j.canlet.2012.01.038] [Cited by in Crossref: 109] [Cited by in F6Publishing: 105] [Article Influence: 12.1] [Reference Citation Analysis]
134 Tan W, Lim SG, Tan TM. Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1. World J Gastroenterol 2015;21:13030-41. [PMID: 26676187 DOI: 10.3748/wjg.v21.i46.13030] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
135 Matsuura K, De Giorgi V, Schechterly C, Wang RY, Farci P, Tanaka Y, Alter HJ. Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C. Hepatology. 2016;64:732-745. [PMID: 27227815 DOI: 10.1002/hep.28660] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
136 Yang Y, Xie Y, Wu M, Geng Y, Li R, Xu L, Liu X, Pan Y. Expression of mmu-miR-96 in the endometrium during early pregnancy and its regulatory effects on stromal cell apoptosis via Bcl2. Mol Med Rep 2017;15:1547-54. [PMID: 28259902 DOI: 10.3892/mmr.2017.6212] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
137 Gougelet A, Colnot S. [microRNA: new diagnostic and therapeutic tools in liver disease?]. Med Sci (Paris). 2013;29:861-867. [PMID: 24148124 DOI: 10.1051/medsci/20132910013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
138 Lim L, Tran BM, Vincan E, Locarnini S, Warner N. HBV-related hepatocellular carcinoma: the role of integration, viral proteins and miRNA. Future Virology 2012;7:1237-49. [DOI: 10.2217/fvl.12.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
139 Diaz G, Melis M, Tice A, Kleiner DE, Mishra L, Zamboni F, Farci P. Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer. 2013;133:816-824. [PMID: 23390000 DOI: 10.1002/ijc.28075] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
140 Kanzaki H, Ito S, Hanafusa H, Jitsumori Y, Tamaru S, Shimizu K, Ouchida M. Identification of direct targets for the miR-17-92 cluster by proteomic analysis. Proteomics 2011;11:3531-9. [DOI: 10.1002/pmic.201000501] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
141 Li S, Wei X, He J, Cao Q, Du D, Zhan X, Zeng Y, Yuan S, Sun L. The comprehensive landscape of miR-34a in cancer research. Cancer Metastasis Rev 2021. [PMID: 33959850 DOI: 10.1007/s10555-021-09973-3] [Reference Citation Analysis]
142 Zhang Z, Chu SF, Wang SS, Jiang YN, Gao Y, Yang PF, Ai QD, Chen NH. RTP801 is a critical factor in the neurodegeneration process of A53T α-synuclein in a mouse model of Parkinson's disease under chronic restraint stress. Br J Pharmacol 2018;175:590-605. [PMID: 29130486 DOI: 10.1111/bph.14091] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
143 Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X, Song L. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 2010;5:e15797. [PMID: 21203424 DOI: 10.1371/journal.pone.0015797] [Cited by in Crossref: 134] [Cited by in F6Publishing: 130] [Article Influence: 12.2] [Reference Citation Analysis]
144 Wright T, Wang Y, Bedford MT. The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma. Epigenomes 2021;5:2. [PMID: 33768972 DOI: 10.3390/epigenomes5010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
145 Sun Y, Liu Y, Cogdell D, Calin GA, Sun B, Kopetz S, Hamilton SR, Zhang W. Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget. 2016;7:11434-11449. [PMID: 26863633 DOI: 10.18632/oncotarget.7196] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
146 George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis. 2015;35:63-74. [PMID: 25632936 DOI: 10.1055/s-0034-1397350] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
147 Lin N, Davis A, Bahr S, Borgschulte T, Achtien K, Kayser K. Profiling highly conserved microrna expression in recombinant IgG-producing and parental Chinese hamster ovary cells. Biotechnol Progress 2011;27:1163-71. [DOI: 10.1002/btpr.556] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
148 Kalinina O, Marchio A, Urbanskii AI, Tarkova AB, Rebbani K, Granov DA, Dejean A, Generalov MI, Pineau P. Somatic changes in primary liver cancer in Russia: A pilot study. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2013;755:90-9. [DOI: 10.1016/j.mrgentox.2013.06.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
149 Zhao Y, Ran Z, Jiang Q, Hu N, Yu B, Zhu L, Shen L, Zhang S, Chen L, Chen H, Jiang J, Chen D. Vitamin D Alleviates Rotavirus Infection through a Microrna-155-5p Mediated Regulation of the TBK1/IRF3 Signaling Pathway In Vivo and In Vitro. Int J Mol Sci 2019;20:E3562. [PMID: 31330869 DOI: 10.3390/ijms20143562] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
150 Yang Z, Zhang Y, Zhang X, Zhang M, Liu H, Zhang S, Qi B, Sun X. Serum microRNA-221 functions as a potential diagnostic and prognostic marker for patients with osteosarcoma. Biomedicine & Pharmacotherapy 2015;75:153-8. [DOI: 10.1016/j.biopha.2015.07.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
151 Baffy G. MicroRNAs in Nonalcoholic Fatty Liver Disease. J Clin Med. 2015;4:1977-1988. [PMID: 26690233 DOI: 10.3390/jcm4121953] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
152 Ling H, Calin GA. The Role of MicroRNAs and Ultraconserved Non-Coding RNAs in Cancer. Cancer Genomics. Elsevier; 2014. pp. 435-47. [DOI: 10.1016/b978-0-12-396967-5.00025-6] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
153 Mandujano-tinoco EA, Garcia-venzor A, Muñoz-galindo L, Lizarraga-sanchez F, Favela-orozco A, Chavez-gutierrez E, Krötzsch E, Salgado RM, Melendez-zajgla J, Maldonado V. miRNA expression profile in multicellular breast cancer spheroids. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2017;1864:1642-55. [DOI: 10.1016/j.bbamcr.2017.05.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
154 Jiang ZC, Tang XM, Zhao YR, Zheng L. A functional variant at miR-34a binding site in toll-like receptor 4 gene alters susceptibility to hepatocellular carcinoma in a Chinese Han population. Tumour Biol. 2014;35:12345-12352. [PMID: 25179842 DOI: 10.1007/s13277-014-2547-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
155 Võsa U, Vooder T, Kolde R, Fischer K, Välk K, Tõnisson N, Roosipuu R, Vilo J, Metspalu A, Annilo T. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer 2011;50:812-22. [PMID: 21748820 DOI: 10.1002/gcc.20902] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 8.5] [Reference Citation Analysis]
156 Vojtechova Z, Tachezy R. The Role of miRNAs in Virus-Mediated Oncogenesis. Int J Mol Sci 2018;19:E1217. [PMID: 29673190 DOI: 10.3390/ijms19041217] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
157 Franzoni S, Morbioli L, Turtoro A, Solazzo L, Greco A, Arbitrio M, Tagliaferri P, Tassone P, Di Martino MT, Breda M. Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS. J Pharm Biomed Anal 2020;188:113451. [PMID: 32659676 DOI: 10.1016/j.jpba.2020.113451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Yin W, Zhao Y, Ji YJ, Tong LP, Liu Y, He SX, Wang AQ. Serum/plasma microRNAs as biomarkers for HBV-related hepatocellular carcinoma in China. Biomed Res Int. 2015;2015:965185. [PMID: 25688372 DOI: 10.1155/2015/965185] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
159 Baida G, Bhalla P, Kirsanov K, Lesovaya E, Yakubovskaya M, Yuen K, Guo S, Lavker RM, Readhead B, Dudley JT, Budunova I. REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids. EMBO Mol Med 2015;7:42-58. [PMID: 25504525 DOI: 10.15252/emmm.201404601] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
160 Ahmed MY, Salah MM, Kassim SK, Abdelaal A, Elayat WM, Mohamed DA, Fouly AE, Abu-Zahra FAE. Evaluation of the diagnostic and therapeutic roles of non-coding RNA and cell proliferation related gene association in hepatocellular carcinoma. Gene 2019;706:97-105. [PMID: 31034943 DOI: 10.1016/j.gene.2019.04.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
161 Saumet A, Mathelier A, Lecellier CH. The potential of microRNAs in personalized medicine against cancers. Biomed Res Int 2014;2014:642916. [PMID: 25243170 DOI: 10.1155/2014/642916] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
162 Mahgoub A, Steer CJ. MicroRNAs in the Evaluation and Potential Treatment of Liver Diseases. J Clin Med 2016;5:E52. [PMID: 27171116 DOI: 10.3390/jcm5050052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
163 Zheng J, Sadot E, Vigidal JA, Klimstra DS, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Ventura A. Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS One 2018;13:e0200776. [PMID: 30052636 DOI: 10.1371/journal.pone.0200776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
164 Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011;140:1618-1628.e16. [PMID: 21324318 DOI: 10.1053/j.gastro.2011.02.009] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 15.3] [Reference Citation Analysis]
165 Li J, Wang Y, Yu W, Chen J, Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochemical and Biophysical Research Communications 2011;406:70-3. [DOI: 10.1016/j.bbrc.2011.01.111] [Cited by in Crossref: 144] [Cited by in F6Publishing: 143] [Article Influence: 14.4] [Reference Citation Analysis]
166 Lendvai G, Kiss A, Kovalszky I, Schaff Z. [MicroRNAs in hepatocarcinogenesis]. Orv Hetil 2012;153:978-89. [PMID: 22714032 DOI: 10.1556/OH.2012.29387] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
167 Galardi S, Mercatelli N, Farace MG, Ciafrè SA. NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 2011;39:3892-3902. [PMID: 21245048 DOI: 10.1093/nar/gkr006] [Cited by in Crossref: 130] [Cited by in F6Publishing: 125] [Article Influence: 13.0] [Reference Citation Analysis]
168 Tao J, Jiang L, Chen X. Roles of microRNA in liver cancer. Liver Research 2018;2:61-72. [DOI: 10.1016/j.livres.2018.06.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
169 Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer. 2014;3:71-84. [PMID: 24944998 DOI: 10.1159/000343863] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 15.1] [Reference Citation Analysis]
170 Panarelli NC, Yantiss RK. MicroRNA Expression in Selected Carcinomas of the Gastrointestinal Tract. Patholog Res Int 2011;2011:124608. [PMID: 21403819 DOI: 10.4061/2011/124608] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
171 Chu H, Wang M, Shi D, Ma L, Zhang Z, Tong N, Huo X, Wang W, Luo D, Gao Y, Zhang Z. Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PLoS One 2011;6:e18108. [PMID: 21483822 DOI: 10.1371/journal.pone.0018108] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
172 Kapadia CH, Luo B, Dang MN, Irvin-Choy N, Valcourt DM, Day ES. Polymer nanocarriers for MicroRNA delivery. J Appl Polym Sci 2020;137:48651. [PMID: 33384460 DOI: 10.1002/app.48651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
173 Chen L, Chen Y, Feng YL, Zhu Y, Wang LQ, Hu S, Cheng P. Tumor circulome in the liquid biopsies for digestive tract cancer diagnosis and prognosis. World J Clin Cases 2020;8:2066-80. [PMID: 32548136 DOI: 10.12998/wjcc.v8.i11.2066] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
174 Gorbatenko A, Søkilde R, Sorensen EE, Newie I, Persson H, Morancho B, Arribas J, Litman T, Rovira C, Pedersen SF. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503. Sci Rep 2019;9:3352. [PMID: 30833639 DOI: 10.1038/s41598-019-39733-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
175 Mukohyama J, Isobe T, Hu Q, Hayashi T, Watanabe T, Maeda M, Yanagi H, Qian X, Yamashita K, Minami H, Mimori K, Sahoo D, Kakeji Y, Suzuki A, Dalerba P, Shimono Y. miR-221 Targets QKI to Enhance the Tumorigenic Capacity of Human Colorectal Cancer Stem Cells. Cancer Res 2019;79:5151-8. [PMID: 31416845 DOI: 10.1158/0008-5472.CAN-18-3544] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 14.5] [Reference Citation Analysis]
176 Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010;102:706-721. [PMID: 20388878 DOI: 10.1093/jnci/djq102] [Cited by in Crossref: 236] [Cited by in F6Publishing: 214] [Article Influence: 21.5] [Reference Citation Analysis]
177 Bertucci A, Prasetyanto EA, Septiadi D, Manicardi A, Brognara E, Gambari R, Corradini R, De Cola L. Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells. Small 2015;11:5687-95. [PMID: 26395266 DOI: 10.1002/smll.201500540] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 12.5] [Reference Citation Analysis]
178 Kannan M, Jayamohan S, Moorthy RK, Chabattula SC, Ganeshan M, Arockiam AJV. AEG-1/miR-221 Axis Cooperatively Regulates the Progression of Hepatocellular Carcinoma by Targeting PTEN/PI3K/AKT Signaling Pathway. Int J Mol Sci 2019;20:E5526. [PMID: 31698701 DOI: 10.3390/ijms20225526] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
179 Roy S, Benz F, Alder J, Bantel H, Janssen J, Vucur M, Gautheron J, Schneider A, Schüller F, Loosen S, Luedde M, Koch A, Tacke F, Luedde T, Trautwein C, Roderburg C. Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. Clinical Science 2016;130:1197-207. [DOI: 10.1042/cs20160216] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 7.8] [Reference Citation Analysis]
180 Jia HY, Wang YX, Yan WT, Li HY, Tian YZ, Wang SM, Zhao HL. MicroRNA-125b functions as a tumor suppressor in hepatocellular carcinoma cells. Int J Mol Sci 2012;13:8762-74. [PMID: 22942733 DOI: 10.3390/ijms13078762] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 6.4] [Reference Citation Analysis]
181 Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 2016;46:391-406. [PMID: 26490438 DOI: 10.1111/hepr.12606] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
182 Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S, De Petro G. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer. 2013;12:162. [PMID: 24330766 DOI: 10.1186/1476-4598-12-162] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
183 Gupta M, Chandan K, Sarwat M. Role of microRNA and Long Non-Coding RNA in Hepatocellular Carcinoma. Curr Pharm Des 2020;26:415-28. [PMID: 31939724 DOI: 10.2174/1381612826666200115093835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
184 Anwar SL, Lehmann U. MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. J Clin Med. 2015;4:1631-1650. [PMID: 26295264 DOI: 10.3390/jcm4081631] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
185 Shehab-Eldeen S, Nada A, Abou-Elela D, El-Naidany S, Arafat E, Omar T. Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC). Asian Pac J Cancer Prev 2019;20:2515-22. [PMID: 31450927 DOI: 10.31557/APJCP.2019.20.8.2515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Correa-Gallego C, Maddalo D, Doussot A, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Betel D, Klimstra D, Jarnagin WR, Ventura A. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS One 2016;11:e0163699. [PMID: 27685844 DOI: 10.1371/journal.pone.0163699] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
187 Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J. 2014;11:64. [PMID: 24690114 DOI: 10.1186/1743-422x-11-64] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
188 Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med. 2013;7:242-254. [PMID: 23681888 DOI: 10.1007/s11684-013-0256-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
189 Lai CY, Yeh KY, Lin CY, Hsieh YW, Lai HH, Chen JR, Hsu CC, Her GM. MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling. Cancers (Basel) 2021;13:940. [PMID: 33668153 DOI: 10.3390/cancers13050940] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
190 Zhang HF, Wang YC, Han YD. MicroRNA‑34a inhibits liver cancer cell growth by reprogramming glucose metabolism. Mol Med Rep 2018;17:4483-9. [PMID: 29328457 DOI: 10.3892/mmr.2018.8399] [Cited by in Crossref: 7] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
191 Sidhu K, Kapoor NR, Pandey V, Kumar V. The “Macro” World of microRNAs in Hepatocellular Carcinoma. Front Oncol. 2015;5:68. [PMID: 25859429 DOI: 10.3389/fonc.2015.00068] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
192 Elfimova N, Sievers E, Eischeid H, Kwiecinski M, Noetel A, Hunt H, Becker D, Frommolt P, Quasdorff M, Steffen HM. Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration. Biochim Biophys Acta. 2013;1833:1190-1198. [PMID: 23391410 DOI: 10.1016/j.bbamcr.2013.01.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
193 Yuan Q, Loya K, Rani B, Möbus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology. 2013;57:299-310. [PMID: 22821679 DOI: 10.1002/hep.25984] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 12.1] [Reference Citation Analysis]
194 Lin C, Chao P, Shen C, Shu J, Yen S, Huang C, Liu J. Novel Target Genes Responsive to Apoptotic Activity by Ocimum gratissimum in Human Osteosarcoma Cells. Am J Chin Med 2014;42:743-67. [DOI: 10.1142/s0192415x14500487] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 2.9] [Reference Citation Analysis]
195 Singh B, Ronghe AM, Chatterjee A, Bhat NK, Bhat HK. MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis 2013;34:1165-72. [PMID: 23492819 DOI: 10.1093/carcin/bgt026] [Cited by in F6Publishing: 98] [Reference Citation Analysis]
196 Wang X, Chen K, Guo G, Chen JL. Noncoding RNAs and their functional involvement in regulation of chronic myeloid leukemia. Brief Funct Genomics 2016;15:239-48. [PMID: 26647283 DOI: 10.1093/bfgp/elv059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
197 Lin LL, Wang W, Hu Z, Wang LW, Chang J, Qian H. Negative feedback of miR-29 family TET1 involves in hepatocellular cancer. Med Oncol. 2014;31:291. [PMID: 25367851 DOI: 10.1007/s12032- 014-0291-2] [Reference Citation Analysis]
198 Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55. [PMID: 23479461 DOI: 10.18632/oncotarget.820] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 13.3] [Reference Citation Analysis]
199 Yang F, Li QJ, Gong ZB, Zhou L, You N, Wang S, Li XL, Li JJ, An JZ, Wang DS. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment. Technol Cancer Res Treat. 2014;13:77-86. [PMID: 23862748 DOI: 10.7785/tcrt.2012.500364] [Cited by in Crossref: 100] [Cited by in F6Publishing: 96] [Article Influence: 12.5] [Reference Citation Analysis]
200 Amini S, Abak A, Sakhinia E, Abhari A. MicroRNA-221 and MicroRNA-222 in Common Human Cancers: Expression, Function, and Triggering of Tumor Progression as a Key Modulator. Lab Med 2019;50:333-47. [PMID: 31049571 DOI: 10.1093/labmed/lmz002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
201 Zhang ZZ, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL, Liang Z. Hepatitis B virus and hepatocellular carcinoma at the miRNA level. World J Gastroenterol. 2011;17:3353-3358. [PMID: 21876625 DOI: 10.3748/wjg.v17.i28.3353] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
202 Xiao Z, Cheng G, Jiao Y, Pan C, Li R, Jia D, Zhu J, Wu C, Zheng M, Jia J. Holo-Seq: single-cell sequencing of holo-transcriptome. Genome Biol 2018;19:163. [PMID: 30333049 DOI: 10.1186/s13059-018-1553-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
203 Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol. 2014;52:445-451. [PMID: 24871972 DOI: 10.1007/s12275-014-4267-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
204 Hanin G, Soreq H. Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes. Front Mol Neurosci 2011;4:28. [PMID: 22007158 DOI: 10.3389/fnmol.2011.00028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
205 Kerr TA, Korenblat KM, Davidson NO. MicroRNAs and liver disease. Transl Res. 2011;157:241-252. [PMID: 21420035 DOI: 10.1016/j.trsl.2011.01.008] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 7.4] [Reference Citation Analysis]
206 Zhang G, Wang Q, Xu R. Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics 2010;11:311-25. [PMID: 21286309 DOI: 10.2174/138920210791616671] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
207 Ramesh V, Ganesan K. Integrative analysis of transcriptome and miRNome unveils the key regulatory connections involved in different stages of hepatocellular carcinoma. Genes Cells 2016;21:949-65. [PMID: 27465470 DOI: 10.1111/gtc.12396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
208 Ma Y, Yang HZ, Dong BJ, Zou HB, Zhou Y, Kong XM, Huang YR. Biphasic regulation of autophagy by miR-96 in prostate cancer cells under hypoxia. Oncotarget 2014;5:9169-82. [PMID: 25333253 DOI: 10.18632/oncotarget.2396] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
209 Shibata C, Otsuka M, Kishikawa T, Ohno M, Yoshikawa T, Takata A, Koike K. Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma. World J Hepatol. 2015;7:1-6. [PMID: 25624991 DOI: 10.4254/wjh.v7.i1.1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
210 Ezzine S, Vassaux G, Pitard B, Barteau B, Malinge JM, Midoux P, Pichon C, Baril P. RILES, a novel method for temporal analysis of the in vivo regulation of miRNA expression. Nucleic Acids Res 2013;41:e192. [PMID: 24013565 DOI: 10.1093/nar/gkt797] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
211 Li Y, Liu M, Zhang Y, Han C, You J, Yang J, Cao C, Jiao S. Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221. Tumour Biol 2013;34:3545-54. [PMID: 23801152 DOI: 10.1007/s13277-013-0933-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
212 Song S, Abdelmohsen K, Zhang Y, Becker KG, Gorospe M, Bernier M. Impact of pyrrolidine dithiocarbamate and interleukin-6 on mammalian target of rapamycin complex 1 regulation and global protein translation. J Pharmacol Exp Ther 2011;339:905-13. [PMID: 21917559 DOI: 10.1124/jpet.111.185678] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
213 Chen W, Hu Q, Qiu M, Zhong S, Xu J, Tang J, Zhao J. miR-221/222: promising biomarkers for breast cancer. Tumor Biol 2013;34:1361-70. [DOI: 10.1007/s13277-013-0750-y] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
214 Agami R. microRNAs, RNA binding proteins and cancer. Eur J Clin Invest 2010;40:370-4. [PMID: 20486997 DOI: 10.1111/j.1365-2362.2010.02279.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
215 Gong J, He XX, Tian A. Emerging role of microRNA in hepatocellular carcinoma (Review). Oncol Lett 2015;9:1027-33. [PMID: 25663852 DOI: 10.3892/ol.2014.2816] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
216 Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer. 2014;3:71-84. [PMID: 24944998 DOI: 10.1159/ 000343863] [Reference Citation Analysis]
217 Pascut D, Hoang M, Nguyen NNQ, Pratama MY, Tiribelli C. HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers (Basel) 2021;13:2485. [PMID: 34069740 DOI: 10.3390/cancers13102485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Lendvai G, Jármay K, Karácsony G, Halász T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A. Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. World J Gastroenterol. 2014;20:15343-15350. [PMID: 25386083 DOI: 10.3748/wjg.v20.i41.15343] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
219 Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. J Hematol Oncol 2010;3:37. [PMID: 20925959 DOI: 10.1186/1756-8722-3-37] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 6.9] [Reference Citation Analysis]
220 ElHefnawi M, Soliman B, Abu-Shahba N, Amer M. An integrative meta-analysis of microRNAs in hepatocellular carcinoma. Genomics Proteomics Bioinformatics. 2013;11:354-367. [PMID: 24287119 DOI: 10.1016/j.gpb.2013.05.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
221 Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res 2021;149:63-101. [PMID: 33579428 DOI: 10.1016/bs.acr.2020.10.002] [Reference Citation Analysis]
222 Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, Ooi LL, Lee CG. MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012;26:3032-3041. [PMID: 22459148 DOI: 10.1096/fj.11-201855] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 8.2] [Reference Citation Analysis]
223 Tan SB, Huang C, Chen X, Wu Y, Zhou M, Zhang C, Zhang Y. Small molecular inhibitors of miR-1 identified from photocycloadducts of acetylenes with 2-methoxy-1,4-naphthalenequinone. Bioorg Med Chem 2013;21:6124-31. [PMID: 23685176 DOI: 10.1016/j.bmc.2013.04.058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
224 Zhu Z, Zhang X, Wang G, Zheng H. Role of MicroRNAs in Hepatocellular Carcinoma. Hepat Mon. 2014;14:e18672. [PMID: 25337143 DOI: 10.5812/hepatmon.18672] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
225 Bazot Q, Paschos K, Skalska L, Kalchschmidt JS, Parker GA, Allday MJ. Epstein-Barr Virus Proteins EBNA3A and EBNA3C Together Induce Expression of the Oncogenic MicroRNA Cluster miR-221/miR-222 and Ablate Expression of Its Target p57KIP2. PLoS Pathog 2015;11:e1005031. [PMID: 26153983 DOI: 10.1371/journal.ppat.1005031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
226 Fang Y, Zhang L, Li Z, Li Y, Huang C, Lu X. MicroRNAs in DNA Damage Response, Carcinogenesis, and Chemoresistance. MiRNAs in Differentiation and Development. Elsevier; 2017. pp. 1-49. [DOI: 10.1016/bs.ircmb.2017.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
227 Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfò L, Rossi C, Ferrari G, Ghia P, Caligaris-Cappio F. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010;115:3949-59. [PMID: 20203269 DOI: 10.1182/blood-2009-11-254656] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
228 Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH, Wu C, Yang SM, Zeng H, Zou QM, Guo G. MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene. 2015;34:2556-2565. [PMID: 25043310 DOI: 10.1038/onc.2014.214] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 12.6] [Reference Citation Analysis]
229 Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem 2013;46:946-52. [PMID: 23396165 DOI: 10.1016/j.clinbiochem.2013.01.025] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
230 McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene. 2011;30:1969-1983. [PMID: 21258404 DOI: 10.1038/onc.2010.594] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 13.6] [Reference Citation Analysis]
231 Khalifa O, Errafii K, Al-Akl NS, Arredouani A. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers. Dis Markers 2020;2020:8822859. [PMID: 33133304 DOI: 10.1155/2020/8822859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
232 Wang Z, Li X. The role of noncoding RNA in hepatocellular carcinoma. Gland Surg. 2013;2:25-29. [PMID: 25083452 DOI: 10.3978/j.issn.2227-684x.2013.02.07] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
233 Li Y, Umbach DM, Li L. Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma. Melanoma Res 2017;27:527-35. [PMID: 28858076 DOI: 10.1097/CMR.0000000000000388] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
234 Flor I, Bullerdiek J. The dark side of a success story: microRNAs of the C19MC cluster in human tumours. J Pathol 2012;227:270-4. [PMID: 22374805 DOI: 10.1002/path.4014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
235 Huang S, He X. The role of microRNAs in liver cancer progression. Br J Cancer. 2011;104:235-240. [PMID: 21102580 DOI: 10.1038/sj.bjc.6606010] [Cited by in Crossref: 158] [Cited by in F6Publishing: 144] [Article Influence: 14.4] [Reference Citation Analysis]
236 Akhtar MM, Micolucci L, Islam MS, Olivieri F, Procopio AD. Bioinformatic tools for microRNA dissection. Nucleic Acids Res 2016;44:24-44. [PMID: 26578605 DOI: 10.1093/nar/gkv1221] [Cited by in Crossref: 123] [Cited by in F6Publishing: 96] [Article Influence: 20.5] [Reference Citation Analysis]
237 Xie D, Yuan P, Wang D, Jin H, Chen H. Expression and prognostic significance of miR-375 and miR-221 in liver cancer. Oncol Lett 2017;14:2305-9. [PMID: 28781668 DOI: 10.3892/ol.2017.6423] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
238 Andrade F, Nakata A, Gotoh N, Fujita A. Large miRNA survival analysis reveals a prognostic four-biomarker signature for triple negative breast cancer. Genet Mol Biol 2020;43:e20180269. [PMID: 31487369 DOI: 10.1590/1678-4685-GMB-2018-0269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
239 Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim SJ, Park WS. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 2014;33:2557-2567. [PMID: 23728341 DOI: 10.1038/onc.2013.216] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 12.4] [Reference Citation Analysis]
240 Gimenes-Teixeira HL, Lucena-Araujo AR, Dos Santos GA, Zanette DL, Scheucher PS, Oliveira LC, Dalmazzo LF, Silva-Júnior WA, Falcão RP, Rego EM. Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia. Exp Hematol Oncol 2013;2:10. [PMID: 23566596 DOI: 10.1186/2162-3619-2-10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
241 Seven M, Karatas OF, Duz MB, Ozen M. The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future Oncology 2014;10:1027-48. [DOI: 10.2217/fon.13.259] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
242 Zhang P, Yu J, Gui Y, Sun C, Han W. Inhibition of miRNA-222-3p Relieves Staphylococcal Enterotoxin B-Induced Liver Inflammatory Injury by Upregulating Suppressors of Cytokine Signaling 1. Yonsei Med J 2019;60:1093-102. [PMID: 31637892 DOI: 10.3349/ymj.2019.60.11.1093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
243 Andrisani O. Epigenetic mechanisms in hepatitis B virus-associated hepatocellular carcinoma. Hepatoma Res 2021;7:12. [PMID: 33614973 DOI: 10.20517/2394-5079.2020.83] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Matsuzaki J, Suzuki H. Role of MicroRNAs-221/222 in Digestive Systems. J Clin Med 2015;4:1566-77. [PMID: 26258795 DOI: 10.3390/jcm4081566] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
245 Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med. 2010;16:257-267. [PMID: 20493775 DOI: 10.1016/j.molmed.2010.04.001] [Cited by in Crossref: 171] [Cited by in F6Publishing: 166] [Article Influence: 15.5] [Reference Citation Analysis]
246 Lupini L, Pepe F, Ferracin M, Braconi C, Callegari E, Pagotto S, Spizzo R, Zagatti B, Lanuti P, Fornari F, Ghasemi R, Mariani-Costantini R, Bolondi L, Gramantieri L, Calin GA, Sabbioni S, Visone R, Veronese A, Negrini M. Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget 2016;7:31361-71. [PMID: 27120784 DOI: 10.18632/oncotarget.8913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
247 Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65. [PMID: 24172333 DOI: 10.1038/nrd4140] [Cited by in Crossref: 837] [Cited by in F6Publishing: 777] [Article Influence: 119.6] [Reference Citation Analysis]
248 Angelbello AJ, Chen JL, Childs-Disney JL, Zhang P, Wang ZF, Disney MD. Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. Chem Rev 2018;118:1599-663. [PMID: 29322778 DOI: 10.1021/acs.chemrev.7b00504] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 13.7] [Reference Citation Analysis]
249 Eissa S, Matboli M, Sharawy A, El-Sharkawi F. Prognostic and biological significance of microRNA-221 in breast cancer. Gene 2015;574:163-7. [PMID: 26253160 DOI: 10.1016/j.gene.2015.08.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
250 Quintavalle C, Mangani D, Roscigno G, Romano G, Diaz-Lagares A, Iaboni M, Donnarumma E, Fiore D, De Marinis P, Soini Y, Esteller M, Condorelli G. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells. PLoS One 2013;8:e74466. [PMID: 24147153 DOI: 10.1371/journal.pone.0074466] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
251 Rangwala F, Omenetti A, Diehl AM. Cancer stem cells: repair gone awry? J Oncol. 2011;2011:465343. [PMID: 21188169 DOI: 10.1155/2011/465343] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
252 Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang Y, Liu Z, Cao X, Chen P, Liu Z, Chen X, Tao Y, Xu C, Mao J, Cheng C, Li C, Hu Y, Wang L, Chin YE, Shi Y, Siebenlist U, Zhang X. A microRNA 221- and 222-mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells. Gastroenterology 2014;147:847-859.e11. [PMID: 24931456 DOI: 10.1053/j.gastro.2014.06.006] [Cited by in F6Publishing: 94] [Reference Citation Analysis]
253 Tipanee J, Di Matteo M, Tulalamba W, Samara-Kuko E, Keirsse J, Van Ginderachter JA, Chuah MK, VandenDriessche T. Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons. Mol Ther Nucleic Acids 2020;19:1309-29. [PMID: 32160703 DOI: 10.1016/j.omtn.2020.01.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
254 Nadda N, Paul SB, Yadav DP, Kumar S, Sreenivas V, Saraya A, Gamanagatti S, Acharya SK, Shalimar, Nayak B. Prognostic and Therapeutic Potentials of OncomiRs Modulating mTOR Pathways in Virus-Associated Hepatocellular Carcinoma. Front Oncol 2020;10:604540. [PMID: 33614488 DOI: 10.3389/fonc.2020.604540] [Reference Citation Analysis]
255 Shifeng H, Danni W, Pu C, Ping Y, Ju C, Liping Z. Circulating liver-specific miR-122 as a novel potential biomarker for diagnosis of cholestatic liver injury. PLoS One 2013;8:e73133. [PMID: 24086271 DOI: 10.1371/journal.pone.0073133] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
256 Zhang C, Ge S, Hu C, Yang N, Zhang J. MiRNA-218, a new regulator of HMGB1, suppresses cell migration and invasion in non-small cell lung cancer. Acta Biochimica et Biophysica Sinica 2013;45:1055-61. [DOI: 10.1093/abbs/gmt109] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 6.5] [Reference Citation Analysis]
257 Takahashi K, Yan I, Wen HJ, Patel T. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem. 2013;46:946-952. [PMID: 23396165 DOI: 10.1016/j.clinbiochem] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Toh TB, Lim JJ, Chow EK. Epigenetics of hepatocellular carcinoma. Clin Transl Med. 2019;8:13. [PMID: 31056726 DOI: 10.1186/s40169-019-0230-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
259 Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del Basso De Caro M, Martinez-Montero JC, Incoronato M, Nuovo G, Croce CM, Condorelli G. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene 2012;31:858-68. [PMID: 21743492 DOI: 10.1038/onc.2011.280] [Cited by in Crossref: 130] [Cited by in F6Publishing: 122] [Article Influence: 13.0] [Reference Citation Analysis]
260 Ling H, Girnita L, Buda O, Calin GA. Non-coding RNAs: the cancer genome dark matter that matters! Clin Chem Lab Med 2017;55:705-14. [PMID: 27988500 DOI: 10.1515/cclm-2016-0740] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
261 Chen Y, Yang W, Chen Q, Liu Q, Liu J, Zhang Y, Li B, Li D, Nan J, Li X, Wu H, Xiang X, Peng Y, Wang J, Su S, Wang Z. Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks. J Transl Med 2021;19:122. [PMID: 33757544 DOI: 10.1186/s12967-021-02791-9] [Reference Citation Analysis]
262 Abbastabar M, Kheyrollah M, Azizian K, Bagherlou N, Tehrani SS, Maniati M, Karimian A. Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein. DNA Repair (Amst) 2018;69:63-72. [PMID: 30075372 DOI: 10.1016/j.dnarep.2018.07.008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 18.7] [Reference Citation Analysis]
263 Ding F, Hong X, Fan X, Huang S, Lian W, Chen X, Liu Q, Chen Y, Gao F. DDIT4 Novel Mutations in Pancreatic Cancer. Gastroenterol Res Pract 2021;2021:6674404. [PMID: 34007269 DOI: 10.1155/2021/6674404] [Reference Citation Analysis]
264 Lin LL, Wang W, Hu Z, Wang LW, Chang J, Qian H. Negative feedback of miR-29 family TET1 involves in hepatocellular cancer. Med Oncol 2014;31:291. [PMID: 25367851 DOI: 10.1007/s12032-014-0291-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
265 Zhao X, Yang Z, Li G, Li D, Zhao Y, Wu Y, Robson SC, He L, Xu Y, Miao R, Zhao H. The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci China Life Sci 2012;55:906-19. [PMID: 23108868 DOI: 10.1007/s11427-012-4384-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
266 Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce CM, Patel T. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene. 2011;30:4750-4756. [PMID: 21625215 DOI: 10.1038/onc.2011.193] [Cited by in Crossref: 454] [Cited by in F6Publishing: 434] [Article Influence: 45.4] [Reference Citation Analysis]
267 Lu C, Huang X, Zhang X, Roensch K, Cao Q, Nakayama KI, Blazar BR, Zeng Y, Zhou X. miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood. 2011;117:4293-4303. [PMID: 21355095 DOI: 10.1182/blood-2010-12-322503] [Cited by in Crossref: 185] [Cited by in F6Publishing: 181] [Article Influence: 18.5] [Reference Citation Analysis]
268 Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011;71:7608-7616. [PMID: 22009537 DOI: 10.1158/0008-5472.can-11-1144] [Cited by in Crossref: 150] [Cited by in F6Publishing: 95] [Article Influence: 15.0] [Reference Citation Analysis]
269 Oh SE, Park HJ, He L, Skibiel C, Junn E, Mouradian MM. The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress. Redox Biol 2018;19:62-73. [PMID: 30107296 DOI: 10.1016/j.redox.2018.07.021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
270 Nia A, Dhanasekaran R. Genomic Landscape of HCC. Curr Hepatol Rep 2020;19:448-61. [PMID: 33816052 DOI: 10.1007/s11901-020-00553-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
271 Yang H, Li Y, Zhong X, Luo P, Luo P, Sun R, Xie R, Fu D, Ma Y, Cong X, Li W. Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2018;15:4097-104. [PMID: 29541175 DOI: 10.3892/ol.2018.7879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
272 Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194. [PMID: 25247240 DOI: 10.1038/mtna.2014.47] [Cited by in Crossref: 278] [Cited by in F6Publishing: 284] [Article Influence: 39.7] [Reference Citation Analysis]
273 Zaleska K, Przybyła A, Kulcenty K, Wichtowski M, Mackiewicz A, Suchorska W, Murawa D. Wound fluids affect miR-21, miR-155 and miR-221 expression in breast cancer cell lines, and this effect is partially abrogated by intraoperative radiation therapy treatment. Oncol Lett 2017;14:4029-36. [PMID: 28943910 DOI: 10.3892/ol.2017.6718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
274 Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012;12:27-33. [PMID: 22082479 DOI: 10.2174/156652412798376170] [Cited by in Crossref: 207] [Cited by in F6Publishing: 209] [Article Influence: 23.0] [Reference Citation Analysis]
275 Wahid F, Khan T, Kim YY. MicroRNA and diseases: therapeutic potential as new generation of drugs. Biochimie 2014;104:12-26. [PMID: 24859535 DOI: 10.1016/j.biochi.2014.05.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
276 Fornari F, Gramantieri L, Callegari E, Shankaraiah RC, Piscaglia F, Negrini M, Giovannini C. MicroRNAs in Animal Models of HCC. Cancers (Basel) 2019;11:E1906. [PMID: 31805631 DOI: 10.3390/cancers11121906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
277 Wang Z, Lin S, Li JJ, Xu Z, Yao H, Zhu X, Xie D, Shen Z, Sze J, Li K. MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1~let-7d via noncanonical E-box. J Biol Chem. 2011;286:39703-39714. [PMID: 21903590 DOI: 10.1074/jbc.m111.293126] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
278 Ma Y, Liang AJ, Fan YP, Huang YR, Zhao XM, Sun Y, Chen XF. Dysregulation and functional roles of miR-183-96-182 cluster in cancer cell proliferation, invasion and metastasis. Oncotarget 2016;7:42805-25. [PMID: 27081087 DOI: 10.18632/oncotarget.8715] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
279 Yau TO, Wu CW, Dong Y, Tang CM, Ng SS, Chan FK, Sung JJ, Yu J. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer. 2014;111:1765-1771. [PMID: 25233396 DOI: 10.1038/bjc.2014.484] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 9.9] [Reference Citation Analysis]
280 Ghidini M, Braconi C. Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne). 2015;2:36. [PMID: 26131450 DOI: 10.3389/fmed.2015.00036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
281 Lin LL, Wang W, Hu Z, Wang LW, Chang J, Qian H. Erratum to: Negative feedback of miR-29 family TET1 involves in hepatocellular cancer. Med Oncol 2015;32:39. [PMID: 25616722 DOI: 10.1007/s12032-014-0437-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
282 Ji J, Chen H, Liu XP, Wang YH, Luo CL, Zhang WW, Xie W, Wang FB. A miRNA Combination as Promising Biomarker for Hepatocellular Carcinoma Diagnosis: A Study Based on Bioinformatics Analysis. J Cancer. 2018;9:3435-3446. [PMID: 30310500 DOI: 10.7150/jca.26101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
283 Gao P, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol. 2011;54:1177-1184. [PMID: 21145831 DOI: 10.1016/j.jhep.2010.09.023] [Cited by in Crossref: 100] [Cited by in F6Publishing: 104] [Article Influence: 9.1] [Reference Citation Analysis]
284 Zhu G, Liu X, Li H, Yan Y, Hong X, Lin Z. Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21. Int J Immunopathol Pharmacol 2018;32:2058738418814341. [PMID: 30477356 DOI: 10.1177/2058738418814341] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
285 Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 2013;8:e61054. [PMID: 23593387 DOI: 10.1371/journal.pone.0061053] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
286 Zhang QH, Sun HM, Zheng RZ, Li YC, Zhang Q, Cheng P, Tang ZH, Huang F. Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene 2013;527:26-32. [PMID: 23791657 DOI: 10.1016/j.gene.2013.06.006] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 10.0] [Reference Citation Analysis]
287 He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Lett. 2014;344:20-27. [PMID: 24183851 DOI: 10.1016/j.canlet.2013.10.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 257] [Article Influence: 34.1] [Reference Citation Analysis]
288 Sadri Nahand J, Bokharaei-Salim F, Salmaninejad A, Nesaei A, Mohajeri F, Moshtzan A, Tabibzadeh A, Karimzadeh M, Moghoofei M, Marjani A, Yaghoubi S, Keyvani H. microRNAs: Key players in virus-associated hepatocellular carcinoma. J Cell Physiol 2019;234:12188-225. [PMID: 30536673 DOI: 10.1002/jcp.27956] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
289 Hong F, Li Y, Xu Y, Zhu L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J Int Med Res 2013;41:64-71. [PMID: 23569131 DOI: 10.1177/0300060513475759] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 7.5] [Reference Citation Analysis]
290 Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29:4781-4788. [PMID: 22105822 DOI: 10.1200/jco.2011.38.2697] [Cited by in Crossref: 394] [Cited by in F6Publishing: 233] [Article Influence: 39.4] [Reference Citation Analysis]
291 Markopoulos GS, Roupakia E, Tokamani M, Chavdoula E, Hatziapostolou M, Polytarchou C, Marcu KB, Papavassiliou AG, Sandaltzopoulos R, Kolettas E. A step-by-step microRNA guide to cancer development and metastasis. Cell Oncol 2017;40:303-39. [DOI: 10.1007/s13402-017-0341-9] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 21.0] [Reference Citation Analysis]
292 Benz F, Roderburg C, Vargas Cardenas D, Vucur M, Gautheron J, Koch A, Zimmermann H, Janssen J, Nieuwenhuijsen L, Luedde M, Frey N, Tacke F, Trautwein C, Luedde T. U6 is unsuitable for normalization of serum miRNA levels in patients with sepsis or liver fibrosis. Exp Mol Med 2013;45:e42. [PMID: 24052167 DOI: 10.1038/emm.2013.81] [Cited by in Crossref: 96] [Cited by in F6Publishing: 91] [Article Influence: 12.0] [Reference Citation Analysis]
293 Sun J, Lu H, Wang X, Jin H. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal 2013;2013:924206. [PMID: 23431261 DOI: 10.1155/2013/924206] [Cited by in Crossref: 37] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
294 Dambal S, Shah M, Mihelich B, Nonn L. The microRNA-183 cluster: the family that plays together stays together. Nucleic Acids Res 2015;43:7173-88. [PMID: 26170234 DOI: 10.1093/nar/gkv703] [Cited by in Crossref: 108] [Cited by in F6Publishing: 97] [Article Influence: 18.0] [Reference Citation Analysis]
295 Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014;2014:486407. [PMID: 24800233 DOI: 10.1155/2014/486407] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
296 Motawi TK, Shaker OG, El-Maragh SA, Senousy MA. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients. PLOS One. 2015;10:e0137706. [PMID: 26352740 DOI: 10.1371/journal.pone.0137706] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
297 Zhang Q, Pu R, Du Y, Han Y, Su T, Wang H, Cao G. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: potential diagnostic and prognostic markers and therapeutic targets. Cancer Lett. 2012;321:1-12. [PMID: 22425745 DOI: 10.1016/j.canlet.2012.03.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
298 Luedde T. MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma. Hepatology 2010;52:1164-6. [PMID: 20812359 DOI: 10.1002/hep.23854] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
299 Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011;7:517-35. [PMID: 21552419 DOI: 10.7150/ijbs.7.517] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 9.5] [Reference Citation Analysis]
300 Xiao J, Liu Y, Wu F, Liu R, Xie Y, Yang Q, Li Y, Liu M, Li S, Tang H. miR-639 Expression Is Silenced by DNMT3A-Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer Cells. Mol Ther 2020;28:587-98. [PMID: 31843451 DOI: 10.1016/j.ymthe.2019.11.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
301 Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol. 2013;19:5439-5445. [PMID: 24023486 DOI: 10.3748/wjg.v19.i33.5439] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 43] [Article Influence: 7.6] [Reference Citation Analysis]
302 Gelley F, Zadori G, Nemes B, Fassan M, Lendvai G, Sarvary E, Doros A, Gerlei Z, Nagy P, Schaff Z. MicroRNA profile before and after antiviral therapy in liver transplant recipients for hepatitis C virus cirrhosis. J Gastroenterol Hepatol. 2014;29:121-127. [PMID: 24033414 DOI: 10.1111/jgh.12362] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
303 Wang X, Liao X, Huang K, Zeng X, Liu Z, Zhou X, Yu T, Yang C, Yu L, Wang Q, Han C, Zhu G, Ye X, Peng T. Clustered microRNAs hsa-miR-221-3p/hsa-miR-222-3p and their targeted genes might be prognostic predictors for hepatocellular carcinoma. J Cancer 2019;10:2520-33. [PMID: 31258758 DOI: 10.7150/jca.29207] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
304 Shen Y, Lu H, Song G. MiR-221-3p and miR-92a-3p enhances smoking-induced inflammation in COPD. J Clin Lab Anal 2021;35:e23857. [PMID: 34097306 DOI: 10.1002/jcla.23857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
305 Li W, Lebrun DG, Li M. The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma. Chin J Cancer. 2011;30:540-550. [PMID: 21801602 DOI: 10.5732/cjc.011.10197] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
306 Gu Z, Zhang C, Wang J. Gene regulation is governed by a core network in hepatocellular carcinoma. BMC Syst Biol. 2012;6:32. [PMID: 22548756 DOI: 10.1186/1752-0509-6-32] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
307 Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T. The role of microRNAs in human liver cancers. Semin Oncol. 2011;38:752-763. [PMID: 22082761 DOI: 10.1053/j.seminoncol.2011.08.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 7.9] [Reference Citation Analysis]
308 Yang J, Zhang JY, Chen J, Xu Y, Song NH, Yin CJ. Prognostic role of microRNA-221 in various human malignant neoplasms: a meta-analysis of 20 related studies. PLoS One 2014;9:e87606. [PMID: 24475314 DOI: 10.1371/journal.pone.0087606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
309 Lupini L, Bassi C, Ferracin M, Bartonicek N, D'Abundo L, Zagatti B, Callegari E, Musa G, Moshiri F, Gramantieri L, Corrales FJ, Enright AJ, Sabbioni S, Negrini M. miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Front Genet 2013;4:64. [PMID: 23630541 DOI: 10.3389/fgene.2013.00064] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
310 Yu X, Wang Y, Tao S, Sun S. Geniposide plays anti-tumor effects by down-regulation of microRNA-224 in HepG2 and Huh7 cell lines. Exp Mol Pathol 2020;112:104349. [PMID: 31778668 DOI: 10.1016/j.yexmp.2019.104349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
311 Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011;6:e23937. [PMID: 21886843 DOI: 10.1371/journal.pone.0023937] [Cited by in Crossref: 383] [Cited by in F6Publishing: 353] [Article Influence: 38.3] [Reference Citation Analysis]
312 Yu Z, Kim J, He L, Creighton CJ, Gunaratne PH, Hawkins SM, Matzuk MM. Functional analysis of miR-34c as a putative tumor suppressor in high-grade serous ovarian cancer. Biol Reprod 2014;91:113. [PMID: 25273528 DOI: 10.1095/biolreprod.114.121988] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
313 Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53:209-218. [PMID: 20890893 DOI: 10.1002/hep.23922] [Cited by in Crossref: 546] [Cited by in F6Publishing: 531] [Article Influence: 49.6] [Reference Citation Analysis]
314 Subhra Das S, James M, Paul S, Chakravorty N. miRnalyze: an interactive database linking tool to unlock intuitive microRNA regulation of cell signaling pathways. Database (Oxford) 2017;2017. [PMID: 28365733 DOI: 10.1093/database/bax015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
315 Saumet A, Lecellier CH. microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers. Adv Exp Med Biol 2015;888:5-15. [PMID: 26663176 DOI: 10.1007/978-3-319-22671-2_2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
316 Wang Z, Wu N, Tesfaye A, Feinstone S, Kumar A. HCV infection-associated hepatocellular carcinoma in humanized mice. Infect Agent Cancer 2015;10:24. [PMID: 26217396 DOI: 10.1186/s13027-015-0018-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
317 Kim WR, Park EG, Kang KW, Lee SM, Kim B, Kim HS. Expression Analyses of MicroRNAs in Hamster Lung Tissues Infected by SARS-CoV-2. Mol Cells 2020;43:953-63. [PMID: 33199671 DOI: 10.14348/molcells.2020.0177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
318 Huang S, He X. microRNAs: tiny RNA molecules, huge driving forces to move the cell. Protein Cell 2010;1:916-26. [PMID: 21204018 DOI: 10.1007/s13238-010-0116-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
319 Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y, Fu S, Lu L. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2014;25:1279-1287.e1. [PMID: 24935355 DOI: 10.1016/j.jvir.2014.04.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
320 Zekri AN, Youssef AS, El-Desouky ED, Ahmed OS, Lotfy MM, Nassar AA, Bahnassey AA. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumour Biol. 2016;37:12273-12286. [PMID: 27271989 DOI: 10.1007/s13277-016-5097-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 10.6] [Reference Citation Analysis]
321 Hua Y, Larsen N, Kalyana-Sundaram S, Kjems J, Chinnaiyan AM, Peter ME. miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers. BMC Genomics 2013;14:179. [PMID: 23497354 DOI: 10.1186/1471-2164-14-179] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
322 Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011;11:393. [PMID: 21920043 DOI: 10.1186/1471-2407-11-393] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 9.0] [Reference Citation Analysis]
323 Bronte F, Bronte G, Fanale D, Caruso S, Bronte E, Bavetta MG, Fiorentino E, Rolfo C, Bazan V, Di Marco V, Russo A. HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit Rev Oncol Hematol 2016;97:312-21. [PMID: 26603462 DOI: 10.1016/j.critrevonc.2015.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
324 Wilson JA, Sagan SM. Hepatitis C virus and human miR-122: insights from the bench to the clinic. Curr Opin Virol. 2014;7:11-18. [PMID: 24721497 DOI: 10.1016/j.coviro.2014.03.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
325 Dehkordi KA, Chaleshtori MH, Sharifi M, Jalili A, Fathi F, Roshani D, Nikkhoo B, Hakhamaneshi MS, Sani MRM, Ganji-Arjenaki M. Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia. Indian J Hematol Blood Transfus 2017;33:327-32. [PMID: 28824233 DOI: 10.1007/s12288-016-0694-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
326 Lee YG, Kim I, Oh S, Shin DY, Koh Y, Lee KW. Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia. Korean J Intern Med 2019;34:178-83. [PMID: 29172404 DOI: 10.3904/kjim.2017.102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
327 Fittipaldi S, Vasuri F, Bonora S, Degiovanni A, Santandrea G, Cucchetti A, Gramantieri L, Bolondi L, D'Errico A. miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. Dig Dis Sci 2017;62:2397-407. [PMID: 28639131 DOI: 10.1007/s10620-017-4654-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
328 Ding F, Gao F, Zhang S, Lv X, Chen Y, Liu Q. A review of the mechanism of DDIT4 serve as a mitochondrial related protein in tumor regulation. Sci Prog 2021;104:36850421997273. [PMID: 33729069 DOI: 10.1177/0036850421997273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
329 Markopoulos GS, Roupakia E, Tokamani M, Vartholomatos G, Tzavaras T, Hatziapostolou M, Fackelmayer FO, Sandaltzopoulos R, Polytarchou C, Kolettas E. Senescence-associated microRNAs target cell cycle regulatory genes in normal human lung fibroblasts. Exp Gerontol 2017;96:110-22. [PMID: 28658612 DOI: 10.1016/j.exger.2017.06.017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
330 Wang H, Yang G, Yu Y, Gu P. MicroRNA-490-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells via targeting TMOD3. Oncol Lett 2020;20:95. [PMID: 32831914 DOI: 10.3892/ol.2020.11956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Matsuzaki J, Suzuki H, Tsugawa H, Watanabe M, Hossain S, Arai E, Saito Y, Sekine S, Akaike T, Kanai Y. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013;145:1300-1311. [PMID: 23933602 DOI: 10.1053/j.gastro.2013.08.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
332 Deng R, Shen N, Yang Y, Yu H, Xu S, Yang YW, Liu S, Meguellati K, Yan F. Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. Biomaterials 2018;167:80-90. [PMID: 29554483 DOI: 10.1016/j.biomaterials.2018.03.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
333 Gan R, Yang Y, Yang X, Zhao L, Lu J, Meng QH. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther 2014;21:290-6. [PMID: 24924200 DOI: 10.1038/cgt.2014.29] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 10.7] [Reference Citation Analysis]
334 Dodurga Y, Yonguc GN, Avci CB, Bagci G, Gunduz C, Satiroglu-Tufan NL. Investigation of microRNA expression changes in HepG2 cell line in presence of URG4/URGCP and in absence of URG4/URGCP suppressed by RNA interference. Mol Biol Rep 2012;39:11119-24. [PMID: 23053999 DOI: 10.1007/s11033-012-2019-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
335 Wang W, Peng B, Wang D, Ma X, Jiang D, Zhao J, Yu L. Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer. 2011;129:1624-1634. [PMID: 21128228 DOI: 10.1002/ijc.25818] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
336 Qi Z, Zhang T, Song L, Fu H, Luo H, Wu J, Zhao S, Zhang T, Guo L, Jin L, Zhang H, Huang G, Ma T, Wu Y, Huang L. PRAS40 hyperexpression promotes hepatocarcinogenesis. EBioMedicine 2020;51:102604. [PMID: 31901857 DOI: 10.1016/j.ebiom.2019.102604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
337 Wang L, Yue Y, Wang X, Jin H. Function and clinical potential of microRNAs in hepatocellular carcinoma. Oncol Lett. 2015;10:3345-3353. [PMID: 26788134 DOI: 10.3892/ol.2015.3759] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
338 Singh AK, Rooge SB, Varshney A, Vasudevan M, Bhardwaj A, Venugopal SK, Trehanpati N, Kumar M, Geffers R, Kumar V, Sarin SK. Global microRNA expression profiling in the liver biopsies of hepatitis B virus-infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury. Hepatology. 2018;67:1695-1709. [PMID: 29194684 DOI: 10.1002/hep.29690] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
339 Di Martino MT, Gullà A, Gallo Cantafio ME, Altomare E, Amodio N, Leone E, Morelli E, Lio SG, Caracciolo D, Rossi M, Frandsen NM, Tagliaferri P, Tassone P. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One 2014;9:e89659. [PMID: 24586944 DOI: 10.1371/journal.pone.0089659] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 9.6] [Reference Citation Analysis]
340 Tan W, Li Y, Lim SG, Tan TM. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol. 2014;20:5962-5972. [PMID: 24876719 DOI: 10.3748/wjg.v20.i20.5962] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 62] [Article Influence: 10.2] [Reference Citation Analysis]
341 Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease. PLoS One. 2011;6:e23937. [PMID: 21886843 DOI: 10.1371/journal.pone.0023937;] [Reference Citation Analysis]
342 Tessitore A, Cicciarelli G, Del Vecchio F, Gaggiano A, Verzella D, Fischietti M, Mastroiaco V, Vetuschi A, Sferra R, Barnabei R, Capece D, Zazzeroni F, Alesse E. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer 2016;16:3. [PMID: 26728044 DOI: 10.1186/s12885-015-2007-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 10.2] [Reference Citation Analysis]
343 Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014;13:622-638. [PMID: 25011539 DOI: 10.1038/nrd4359] [Cited by in Crossref: 618] [Cited by in F6Publishing: 563] [Article Influence: 88.3] [Reference Citation Analysis]
344 Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C, Wu M. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology. 2013;145:853-864.e9. [PMID: 23770133 DOI: 10.1053/j.gastro.2013.06.008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
345 Chang S, Wang LH, Chen BS. Investigating Core Signaling Pathways of Hepatitis B Virus Pathogenesis for Biomarkers Identification and Drug Discovery via Systems Biology and Deep Learning Method. Biomedicines. 2020;8. [PMID: 32878239 DOI: 10.3390/biomedicines8090320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol. 2012;56:1371-1383. [PMID: 22314424 DOI: 10.1016/j.jhep.2011.11.026] [Cited by in Crossref: 157] [Cited by in F6Publishing: 145] [Article Influence: 17.4] [Reference Citation Analysis]
347 Lu X, Yin B, Wang X, Wang F, Li Y, Wang N, Yang X, Jiang W. Long non-coding RNA-ZNF281 upregulates PTEN expression via downregulation of microRNA-221 in non-small cell lung cancer. Oncol Lett 2020;20:2962-8. [PMID: 32782613 DOI: 10.3892/ol.2020.11821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
348 Hou W, Bonkovsky HL. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol. 2013;19:7836-7845. [PMID: 24307777 DOI: 10.3748/wjg.v19.i44.7836] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
349 Mulvenna J, Yonglitthipagon P, Sripa B, Brindley PJ, Loukas A, Bethony JM. Banking on the future: biobanking for “omics” approaches to biomarker discovery for Opisthorchis-induced cholangiocarcinoma in Thailand. Parasitol Int. 2012;61:173-177. [PMID: 21855650 DOI: 10.1016/j.parint.2011.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
350 Yu MA, Kiang A, Wang-Rodriguez J, Rahimy E, Haas M, Yu V, Ellies LG, Chen J, Fan JB, Brumund KT, Weisman RA, Ongkeko WM. Nicotine promotes acquisition of stem cell and epithelial-to-mesenchymal properties in head and neck squamous cell carcinoma. PLoS One 2012;7:e51967. [PMID: 23300583 DOI: 10.1371/journal.pone.0051967] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
351 Ge Y, Chen J. MicroRNAs in skeletal myogenesis. Cell Cycle 2011;10:441-8. [PMID: 21270519 DOI: 10.4161/cc.10.3.14710] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 9.8] [Reference Citation Analysis]
352 Mao D, Chen H, Tang Y, Li J, Cao Y, Zhao J. Application of Isothermal Nucleic Acid Signal Amplification in the Detection of Hepatocellular Carcinoma-Associated MicroRNA. ChemPlusChem 2019;84:8-17. [DOI: 10.1002/cplu.201800382] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
353 Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Shibata C, Koike K. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. J Gastroenterol. 2014;49:173-184. [PMID: 24258409 DOI: 10.1007/s00535-013-0909-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
354 Bretones G, Delgado MD, León J. Myc and cell cycle control. Biochim Biophys Acta. 2015;1849:506-516. [PMID: 24704206 DOI: 10.1016/j.bbagrm.2014.03.013] [Cited by in Crossref: 294] [Cited by in F6Publishing: 275] [Article Influence: 42.0] [Reference Citation Analysis]
355 Ors-Kumoglu G, Gulce-Iz S, Biray-Avci C. Therapeutic microRNAs in human cancer. Cytotechnology. 2019;71:411-425. [PMID: 30600466 DOI: 10.1007/s10616-018-0291-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
356 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
357 Law PT, Wong N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:437-449. [PMID: 21332540 DOI: 10.1111/j.1440-1746.2010.06512.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
358 Anindo MI, Yaqinuddin A. Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg. 2012;10:443-449. [PMID: 22906693 DOI: 10.1016/j.ijsu.2012.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
359 Marquardt JU, Andersen JB. Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat Oncol. 2015;2:79-93. [PMID: 26257864 DOI: 10.2217/hep.14.24] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
360 van Beijnum JR, Giovannetti E, Poel D, Nowak-Sliwinska P, Griffioen AW. miRNAs: micro-managers of anticancer combination therapies. Angiogenesis 2017;20:269-85. [PMID: 28474282 DOI: 10.1007/s10456-017-9545-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
361 Ning T, Zhang H, Wang X, Li S, Zhang L, Deng T, Zhou L, Wang X, Liu R, Bai M, Ge S, Li H, Huang D, Ying G, Ba Y. miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer. Tumour Biol 2017;39:101042831770163. [DOI: 10.1177/1010428317701636] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
362 Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol 2013;7:206-23. [PMID: 23428636 DOI: 10.1016/j.molonc.2013.01.005] [Cited by in Crossref: 107] [Cited by in F6Publishing: 91] [Article Influence: 13.4] [Reference Citation Analysis]
363 Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2011;30:1082-1097. [PMID: 21057537 DOI: 10.1038/onc.2010.487] [Cited by in Crossref: 246] [Cited by in F6Publishing: 234] [Article Influence: 22.4] [Reference Citation Analysis]
364 Lendvai G, Kiss A, Kovalszky I, Schaff Z. [Alterations in microRNA expression patterns in liver diseases]. Orv Hetil 2010;151:1843-53. [PMID: 20980222 DOI: 10.1556/OH.2010.28985] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
365 Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, Castrillon DH, Kabbani W, Brugarolas J. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol 2011;31:1870-84. [PMID: 21383064 DOI: 10.1128/MCB.01393-10] [Cited by in Crossref: 55] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
366 Han J, Liu S, Zhang Y, Xu Y, Jiang Y, Zhang C, Li C, Li X. MiRSEA: Discovering the pathways regulated by dysfunctional MicroRNAs. Oncotarget 2016;7:55012-25. [PMID: 27474169 DOI: 10.18632/oncotarget.10839] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
367 Gyugos M, Lendvai G, Kenessey I, Schlachter K, Halász J, Nagy P, Garami M, Jakab Z, Schaff Z, Kiss A. MicroRNA expression might predict prognosis of epithelial hepatoblastoma. Virchows Arch. 2014;464:419-427. [PMID: 24570391 DOI: 10.1007/s00428-014-1549-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
368 Ling H, Zhang W, Calin GA. Principles of microRNA involvement in human cancers. Chin J Cancer 2011;30:739-48. [PMID: 22035854 DOI: 10.5732/cjc.011.10243] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
369 Guo J, Jin M, Zhang M, Chen K. A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS One. 2012;7:e30585. [PMID: 22291993 DOI: 10.1371/journal.pone.0030585] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 8.0] [Reference Citation Analysis]
370 Li J, Pandey V, Kessler T, Lehrach H, Wierling C. Modeling of miRNA and drug action in the EGFR signaling pathway. PLoS One 2012;7:e30140. [PMID: 22253908 DOI: 10.1371/journal.pone.0030140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
371 Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, Goga A. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology 2014;59:202-15. [PMID: 23913442 DOI: 10.1002/hep.26662] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 10.1] [Reference Citation Analysis]
372 Wang M, Wang W, Wang J, Zhang J. MiR-182 promotes glucose metabolism by upregulating hypoxia-inducible factor 1α in NSCLC cells. Biochem Biophys Res Commun 2018;504:400-5. [PMID: 29894685 DOI: 10.1016/j.bbrc.2018.06.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
373 Pea A, Jamieson NB, Braconi C. Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:38-48. [PMID: 32160335 DOI: 10.1002/hep.31225] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
374 Halász T, Horváth G, Pár G, Werling K, Kiss A, Schaff Z, Lendvai G. miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol. 2015;21:7814-7823. [PMID: 26167081 DOI: 10.3748/wjg.v21.i25.7814] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
375 Zhao D, Zhuang N, Ding Y, Kang Y, Shi L. MiR-221 activates the NF-κB pathway by targeting A20. Biochem Biophys Res Commun 2016;472:11-8. [PMID: 26549234 DOI: 10.1016/j.bbrc.2015.11.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
376 Luo Z, Zhang M, Cui R, Tili E, Kim T, Lee TJ, Peng Y, Croce C. A negative feedback regulatory loop between miR-138 and TP53 is mediated by USP10. Oncotarget 2019;10:6288-96. [PMID: 31695837 DOI: 10.18632/oncotarget.27275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
377 Dentelli P, Rosso A, Orso F, Olgasi C, Taverna D, Brizzi MF. microRNA-222 Controls Neovascularization by Regulating Signal Transducer and Activator of Transcription 5A Expression. ATVB 2010;30:1562-8. [DOI: 10.1161/atvbaha.110.206201] [Cited by in Crossref: 137] [Cited by in F6Publishing: 85] [Article Influence: 12.5] [Reference Citation Analysis]
378 Xue J, Niu J, Wu J, Wu ZH. MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol. 2014;5:730-743. [PMID: 25302173 DOI: 10.5306/wjco.v5.i4.730] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
379 Nakka M, Allen-Rhoades W, Li Y, Kelly AJ, Shen J, Taylor AM, Barkauskas DA, Yustein JT, Andrulis IL, Wunder JS, Gorlick R, Meltzer PS, Lau CC, Man TK; TARGET osteosarcoma consortium. Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. Oncotarget 2017;8:96738-52. [PMID: 29228567 DOI: 10.18632/oncotarget.18236] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
380 Ma S, Sun J, Guo Y, Zhang P, Liu Y, Zheng D, Shi J. Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer. Theranostics 2017;7:3228-42. [PMID: 28900506 DOI: 10.7150/thno.19893] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
381 Pollutri D, Gramantieri L, Bolondi L, Fornari F. TP53/MicroRNA Interplay in Hepatocellular Carcinoma. Int J Mol Sci. 2016;17. [PMID: 27918441 DOI: 10.3390/ijms17122029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
382 Bimonte S, Leongito M, Barbieri A, Del Vecchio V, Falco M, Giudice A, Palaia R, Albino V, Di Giacomo R, Petrillo A, Granata V, Izzo F. The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells. Stem Cells Int 2016;2016:1065230. [PMID: 27118975 DOI: 10.1155/2016/1065230] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
383 Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negrini M. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22:46-57. [PMID: 25190143 DOI: 10.1038/cdd.2014.136] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 12.1] [Reference Citation Analysis]
384 Roderburg C, Mollnow T, Bongaerts B, Elfimova N, Vargas Cardenas D, Berger K, Zimmermann H, Koch A, Vucur M, Luedde M, Hellerbrand C, Odenthal M, Trautwein C, Tacke F, Luedde T. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One. 2012;7:e32999. [PMID: 22412969 DOI: 10.1371/journal.pone.0032999] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 7.7] [Reference Citation Analysis]
385 Yilmaz SS, Guzel E, Karatas OF, Yilmaz M, Creighton CJ, Ozen M. MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients. Laryngoscope 2015;125:E377-81. [PMID: 25945817 DOI: 10.1002/lary.25332] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
386 Yacoub RA, Fawzy IO, Assal RA, Hosny KA, Zekri AN, Esmat G, El Tayebi HM, Abdelaziz AI. miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. J Clin Transl Hepatol 2016;4:300-5. [PMID: 28097098 DOI: 10.14218/JCTH.2016.00031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
387 Ouchida M, Kanzaki H, Ito S, Hanafusa H, Jitsumori Y, Tamaru S, Shimizu K. Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One 2012;7:e44095. [PMID: 22952885 DOI: 10.1371/journal.pone.0044095] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
388 Cui X, Zhang A, Liu J, Wu K, Chen Z, Wang Q. Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression. Biochemical and Biophysical Research Communications 2018;504:784-91. [DOI: 10.1016/j.bbrc.2018.08.076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
389 Shih YT, Wang MC, Zhou J, Peng HH, Lee DY, Chiu JJ. Endothelial progenitors promote hepatocarcinoma intrahepatic metastasis through monocyte chemotactic protein-1 induction of microRNA-21. Gut. 2015;64:1132-1147. [PMID: 24939570 DOI: 10.1136/gutjnl-2013-306302] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
390 Nedaeinia R, Avan A, Ahmadian M, Nia SN, Ranjbar M, Sharifi M, Goli M, Piroozmand A, Nourmohammadi E, Manian M, Ferns GA, Ghayour-Mobarhan M, Salehi R. Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer. J Cell Biochem 2017;118:4129-40. [PMID: 28401648 DOI: 10.1002/jcb.26047] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
391 Liu X, Zhang H, Zhou P, Yu Y, Zhang H, Chen L, Gong J, Liu Z. CREB1 acts via the miR‑922/ARID2 axis to enhance malignant behavior of liver cancer cells. Oncol Rep 2021;45:79. [PMID: 33786634 DOI: 10.3892/or.2021.8030] [Reference Citation Analysis]
392 von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut. 2020;69:2025-2034. [PMID: 32883873 DOI: 10.1136/gutjnl-2019-320282] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
393 Wang J, Li LC. Small RNA and its application in andrology and urology. Transl Androl Urol 2012;1:33-43. [PMID: 23002430 DOI: 10.3978/j.issn.2223-4683.2011.12.04] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
394 Li J, Bei Y, Liu Q, Lv D, Xu T, He Y, Chen P, Xiao J. MicroRNA-221 is required for proliferation of mouse embryonic stem cells via P57 targeting. Stem Cell Rev Rep 2015;11:39-49. [PMID: 25086570 DOI: 10.1007/s12015-014-9543-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
395 Tirado-Hurtado I, Fajardo W, Pinto JA. DNA Damage Inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer. Front Oncol 2018;8:106. [PMID: 29707520 DOI: 10.3389/fonc.2018.00106] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
396 Zhou H, Xu Q, Ni C, Ye S, Xu X, Hu X, Jiang J, Hong Y, Huang D, Yang L. Prospects of Noncoding RNAs in Hepatocellular Carcinoma. Biomed Res Int 2018;2018:6579436. [PMID: 30148169 DOI: 10.1155/2018/6579436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
397 Galasso M, Sana ME, Volinia S. Non-coding RNAs: a key to future personalized molecular therapy? Genome Med 2010;2:12. [PMID: 20236487 DOI: 10.1186/gm133] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 6.3] [Reference Citation Analysis]
398 Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 2011;6:e19518. [PMID: 21573166 DOI: 10.1371/journal.pone.0019518] [Cited by in Crossref: 127] [Cited by in F6Publishing: 130] [Article Influence: 12.7] [Reference Citation Analysis]
399 Galasso M, Sandhu SK, Volinia S. MicroRNA expression signatures in solid malignancies. Cancer J. 2012;18:238-243. [PMID: 22647360 DOI: 10.1097/ppo.0b013e318258b5f4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
400 Yu J, Zhang W, Qian H, Tang H, Lin W, Lu B. SOCS1 regulates hepatic regenerative response and provides prognostic makers for acute obstructive cholangitis. Sci Rep 2017;7:9482. [PMID: 28842621 DOI: 10.1038/s41598-017-09865-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
401 Rebbani K, Marchio A, Ezzikouri S, Afifi R, Kandil M, Bahri O, Triki H, El Feydi AE, Dejean A, Benjelloun S, Pineau P. TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma. Mol Cancer 2015;14:74. [PMID: 25889455 DOI: 10.1186/s12943-015-0340-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
402 Dang Y, Luo D, Rong M, Chen G. Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS One. 2013;8:e61054. [PMID: 23593387 DOI: 10.1371/journal.pone.0061054] [Cited by in Crossref: 86] [Cited by in F6Publishing: 87] [Article Influence: 10.8] [Reference Citation Analysis]
403 Zhou C, Liu J, Li Y, Liu L, Zhang X, Ma CY, Hua SC, Yang M, Yuan Q. microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett. 2011;585:1828-1834. [PMID: 21530512 DOI: 10.1016/j.febslet.2011.04.040] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
404 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. Int J Mol Sci 2018;19:E3966. [PMID: 30544653 DOI: 10.3390/ijms19123966] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
405 Wong CM, Wong CC, Lee JM, Fan DN, Au SL, Ng IO. Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology. 2012;55:1453-1461. [PMID: 22135159 DOI: 10.1002/hep.25512] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
406 Valencia-Quintana R, Sánchez-Alarcón J, Tenorio-Arvide MG, Deng Y, Montiel-González JM, Gómez-Arroyo S, Villalobos-Pietrini R, Cortés-Eslava J, Flores-Márquez AR, Arenas-Huertero F. The microRNAs as potential biomarkers for predicting the onset of aflatoxin exposure in human beings: a review. Front Microbiol 2014;5:102. [PMID: 24672518 DOI: 10.3389/fmicb.2014.00102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
407 Peeridogaheh H, Meshkat Z, Habibzadeh S, Arzanlou M, Shahi JM, Rostami S, Gerayli S, Teimourpour R. Current concepts on immunopathogenesis of hepatitis B virus infection. Virus Res. 2018;245:29-43. [PMID: 29273341 DOI: 10.1016/j.virusres.2017.12.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
408 Moses BS, Evans R, Slone WL, Piktel D, Martinez I, Craig MD, Gibson LF. Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia. Mol Cancer Res. 2016;14:909-919. [PMID: 27358112 DOI: 10.1158/1541-7786.mcr-15-0474] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
409 Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res. 2012;72:4037-4046. [PMID: 22761336 DOI: 10.1158/0008-5472.CAN-12-0103] [Cited by in Crossref: 85] [Cited by in F6Publishing: 56] [Article Influence: 9.4] [Reference Citation Analysis]
410 Wang T, Jiang L, Wei X, Dong Z, Liu B, Zhao J, Wang L, Xie P, Wang Y, Zhou S. Inhibition of miR-221 alleviates LPS-induced acute lung injury via inactivation of SOCS1/NF-κB signaling pathway. Cell Cycle 2019;18:1893-907. [PMID: 31208297 DOI: 10.1080/15384101.2019.1632136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
411 Song Q, An Q, Niu B, Lu X, Zhang N, Cao X. Role of miR-221/222 in Tumor Development and the Underlying Mechanism. J Oncol 2019;2019:7252013. [PMID: 31929798 DOI: 10.1155/2019/7252013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
412 Duan Q, Wang X, Gong W, Ni L, Chen C, He X, Chen F, Yang L, Wang P, Wang DW. ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One 2012;7:e31518. [PMID: 22359598 DOI: 10.1371/journal.pone.0031518] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 11.2] [Reference Citation Analysis]
413 Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J. Translational medicine in hepatocellular carcinoma. Front Med. 2012;6:122-133. [PMID: 22573220 DOI: 10.1007/s11684-012-0193-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
414 Gurzu S, Kobori L, Fodor D, Jung I. Epithelial Mesenchymal and Endothelial Mesenchymal Transitions in Hepatocellular Carcinoma: A Review. Biomed Res Int 2019;2019:2962580. [PMID: 31781608 DOI: 10.1155/2019/2962580] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
415 Manna D, Sarkar D. Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1243. [PMID: 32429062 DOI: 10.3390/cancers12051243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
416 Kasinski AL, Slack FJ. Arresting the Culprit: Targeted Antagomir Delivery to Sequester Oncogenic miR-221 in HCC. Mol Ther Nucleic Acids 2012;1:e12. [PMID: 23343881 DOI: 10.1038/mtna.2012.2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
417 Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology. 2013;58:810-818. [PMID: 23408390 DOI: 10.1002/hep.26323] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 8.4] [Reference Citation Analysis]
418 Li L, Diao W, Zen K. Micro-ribonucleic acids: potential noninvasive biomarkers for hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:21-33. [PMID: 27508173 DOI: 10.2147/JHC.S44463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
419 Li XY, Wen JY, Jia CC, Wang TT, Li X, Dong M, Lin QU, Chen ZH, Ma XK, Wei LI, Lin ZX, Ruan DY, Chen J, Wu DH, Liu W, Tai Y, Xiong ZY, Wu XY, Zhang QI. MicroRNA-34a-5p enhances sensitivity to chemotherapy by targeting AXL in hepatocellular carcinoma MHCC-97L cells. Oncol Lett 2015;10:2691-8. [PMID: 26722228 DOI: 10.3892/ol.2015.3654] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
420 Chang L, Li K, Guo T. miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC. Clin Transl Oncol 2017;19:695-703. [PMID: 27864783 DOI: 10.1007/s12094-016-1582-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
421 Teng KY, Barajas JM, Hu P, Jacob ST, Ghoshal K. Role of B Cell Lymphoma 2 in the Regulation of Liver Fibrosis in miR-122 Knockout Mice. Biology (Basel) 2020;9:E157. [PMID: 32650615 DOI: 10.3390/biology9070157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Rajagopalan K, Qiu R, Mooney SM, Rao S, Shiraishi T, Sacho E, Huang H, Shapiro E, Weninger KR, Kulkarni P. The Stress-response protein prostate-associated gene 4, interacts with c-Jun and potentiates its transactivation. Biochim Biophys Acta 2014;1842:154-63. [PMID: 24263171 DOI: 10.1016/j.bbadis.2013.11.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
423 Jiao B, Zhang X, Wang S, Wang L, Luo Z, Zhao H, Khatib H, Wang X. MicroRNA-221 regulates proliferation of bovine mammary gland epithelial cells by targeting the STAT5a and IRS1 genes. Journal of Dairy Science 2019;102:426-35. [DOI: 10.3168/jds.2018-15108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
424 Zhou J, Tao Y, Peng C, Gu P, Wang W. miR-503 regulates metastatic function through Rho guanine nucleotide exchanger factor 19 in hepatocellular carcinoma. J Surg Res 2014;188:129-36. [PMID: 24405610 DOI: 10.1016/j.jss.2013.12.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
425 Finch ML, Marquardt JU, Yeoh GC, Callus BA. Regulation of microRNAs and their role in liver development, regeneration and disease. Int J Biochem Cell Biol. 2014; Apr 13. [Epub ahead of print]. [PMID: 24731940 DOI: 10.1016/j.biocel.2014.04.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
426 Wang L, Yu J, Xu J, Zheng C, Li X, Du J. The analysis of microRNA-34 family expression in human cancer studies comparing cancer tissues with corresponding pericarcinous tissues. Gene 2015;554:1-8. [PMID: 25452192 DOI: 10.1016/j.gene.2014.10.032] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
427 Cui X, Wu Y, Wang Z, Liu X, Wang S, Qin C. MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Tumour Biol. 2015;36:3887-3893. [PMID: 25596083 DOI: 10.1007/s13277-014-3031-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
428 Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell 2019;179:1033-55. [PMID: 31730848 DOI: 10.1016/j.cell.2019.10.017] [Cited by in Crossref: 264] [Cited by in F6Publishing: 215] [Article Influence: 264.0] [Reference Citation Analysis]
429 Mehra M, Chauhan R. Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma. Biomark Cancer 2017;9:1179299X17737301. [PMID: 29147078 DOI: 10.1177/1179299X17737301] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
430 Sasaki R, Kanda T, Yokosuka O, Kato N, Matsuoka S, Moriyama M. Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. Int J Mol Sci 2019;20:E1406. [PMID: 30897788 DOI: 10.3390/ijms20061406] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
431 Huang S, Zhou D, Li YX, Ming ZY, Li KZ, Wu GB, Chen C, Zhao YN. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3. J Cell Physiol 2019;234:3500-14. [PMID: 30370582 DOI: 10.1002/jcp.26863] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
432 Saito Y, Hibino S, Saito H. Alterations of epigenetics and microRNA in hepatocellular carcinoma. Hepatol Res 2014;44:31-42. [PMID: 23617364 DOI: 10.1111/hepr.12147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
433 Zou J, Zhu X, Xiang D, Zhang Y, Li J, Su Z, Kong L, Zhang H. LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1,6-bisphosphatase. Acta Pharm Sin B 2021;11:1578-91. [PMID: 34221869 DOI: 10.1016/j.apsb.2021.02.005] [Reference Citation Analysis]
434 Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203-222. [PMID: 28209991 DOI: 10.1038/nrd.2016.246] [Cited by in Crossref: 1780] [Cited by in F6Publishing: 1669] [Article Influence: 445.0] [Reference Citation Analysis]
435 Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D’Abundo L, Ferracin M, Bassi C. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology. 2012;56:1025-1033. [PMID: 22473819 DOI: 10.1002/hep.25747] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 11.9] [Reference Citation Analysis]
436 Gong N, Gong M. MiRNA-221 from tissue may predict the prognosis of patients with osteosarcoma. Medicine (Baltimore) 2018;97:e11100. [PMID: 30024497 DOI: 10.1097/MD.0000000000011100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
437 Henry JC, Park JK, Jiang J, Kim JH, Nagorney DM, Roberts LR, Banerjee S, Schmittgen TD. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2010;403:120-125. [PMID: 21055388 DOI: 10.1016/j.bbrc.2010.10.130] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 8.7] [Reference Citation Analysis]
438 Kim HS, Lee KS, Bae HJ, Eun JW, Shen Q, Park SJ, Shin WC, Yang HD, Park M, Park WS, Kang YK, Nam SW. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget 2015;6:8089-102. [PMID: 25797269 DOI: 10.18632/oncotarget.3512] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 15.4] [Reference Citation Analysis]
439 Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X, Gan J. A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 2014;9:e107986. [PMID: 25238238 DOI: 10.1371/journal.pone.0107986] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 15.0] [Reference Citation Analysis]
440 Selitsky SR, Dinh TA, Toth CL, Kurtz CL, Honda M, Struck BR, Kaneko S, Vickers KC, Lemon SM, Sethupathy P. Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs. mBio 2015;6:e01500-15. [PMID: 26646011 DOI: 10.1128/mBio.01500-15] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
441 Ji J, Xu X, Wang X, Yao L, Shang H, Li H, Ma J, Bi Y, Xie Q. Expression of dysregulated miRNA in vivo in DF-1 cells during the course of subgroup J avian leukosis virus infection. Microb Pathog 2019;126:40-4. [PMID: 30366127 DOI: 10.1016/j.micpath.2018.10.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
442 Akula SM, Abrams SL, Steelman LS, Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M, McCubrey JA. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets 2019;23:915-29. [PMID: 31657972 DOI: 10.1080/14728222.2019.1685501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
443 Pinno J, Bongartz H, Klepsch O, Wundrack N, Poli V, Schaper F, Dittrich A. Interleukin-6 influences stress-signalling by reducing the expression of the mTOR-inhibitor REDD1 in a STAT3-dependent manner. Cell Signal 2016;28:907-16. [PMID: 27094713 DOI: 10.1016/j.cellsig.2016.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
444 Alqurashi N, Hashimi SM, Wei MQ. Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics. Int J Mol Sci 2013;14:3874-900. [PMID: 23434669 DOI: 10.3390/ijms14023874] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
445 Murakami Y, Tamori A, Itami S, Tanahashi T, Toyoda H, Tanaka M, Wu W, Brojigin N, Kaneoka Y, Maeda A. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer. 2013;13:99. [PMID: 23496901 DOI: 10.1186/1471-2407-13-99] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.9] [Reference Citation Analysis]
446 Hnit SS, Xie C, Yao M, Holst J, Bensoussan A, De Souza P, Li Z, Dong Q. p27(Kip1) signaling: Transcriptional and post-translational regulation. Int J Biochem Cell Biol 2015;68:9-14. [PMID: 26279144 DOI: 10.1016/j.biocel.2015.08.005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
447 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol. 2018;10:558-570. [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
448 Chawla JP, Iyer N, Soodan KS, Sharma A, Khurana SK, Priyadarshni P. Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by Epstein-Barr virus and human papillomaviruses: With special reference to oral cancer. Oral Oncol 2015;51:731-7. [PMID: 26093389 DOI: 10.1016/j.oraloncology.2015.05.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
449 Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD, Pertsemlidis A. miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene. 2014;33:4307-4315. [PMID: 24037530 DOI: 10.1038/onc.2013.381] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
450 Roderburg C, Trautwein C, Luedde T. MicroRNA-199a/b-3p: a new star in the liver microcosmos. Hepatology 2011;54:729-31. [PMID: 21793019 DOI: 10.1002/hep.24456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
451 Gallach S, Calabuig-Fariñas S, Jantus-Lewintre E, Camps C. MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res Int 2014;2014:878450. [PMID: 25197665 DOI: 10.1155/2014/878450] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
452 Song B, Ju J. Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. Expert Rev Mol Med 2010;12:e33. [PMID: 20942990 DOI: 10.1017/S1462399410001663] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
453 Wang Y, Lee CG. Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics. 2011;3:235-243. [PMID: 22122284 DOI: 10.2217/epi.11.5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
454 Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophys Acta 2012;1826:215-37. [PMID: 23393659 DOI: 10.1016/j.bbcan.2012.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 18] [Article Influence: 0.6] [Reference Citation Analysis]
455 Chandel R, Saxena R, Das A, Kaur J. Association of rno‐miR‐183‐96‐182 cluster with diethyinitrosamine induced liver fibrosis in Wistar rats. J Cell Biochem 2018;119:4072-84. [DOI: 10.1002/jcb.26583] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
456 Shah MY, Calin GA. MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA. 2014;5:537-548. [PMID: 24687772 DOI: 10.1002/wrna.1229] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 7.9] [Reference Citation Analysis]
457 He YC, Zhou FL, Shen Y, Liao DF, Cao D. Apoptotic death of cancer stem cells for cancer therapy. Int J Mol Sci. 2014;15:8335-8351. [PMID: 24823879 DOI: 10.3390/ijms15058335] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
458 Roderburg C, Benz F, Vargas Cardenas D, Koch A, Janssen J, Vucur M, Gautheron J, Schneider AT, Koppe C, Kreggenwinkel K, Zimmermann HW, Luedde M, Trautwein C, Tacke F, Luedde T. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int. 2015;35:1172-1184. [PMID: 25039534 DOI: 10.1111/liv.12627] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 11.1] [Reference Citation Analysis]
459 Bae HJ, Jung KH, Eun JW, Shen Q, Kim HS, Park SJ, Shin WC, Yang HD, Park WS, Lee JY, Nam SW. MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer. J Hepatol 2015;63:408-19. [PMID: 25817558 DOI: 10.1016/j.jhep.2015.03.019] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
460 Zheng B, Jeong S, Zhu Y, Chen L, Xia Q. miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA). Oncotarget. 2017;8:100819-100830. [PMID: 29246025 DOI: 10.18632/oncotarget.19044] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
461 Wang J, Song W, Shen W, Yang X, Sun W, Qu S, Shang R, Ma B, Pu M, Tao K. MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma. Oncol Res. 2017;25:1-10. [PMID: 28081727 DOI: 10.3727/096504016x14685034103798] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
462 Qiao J, Du Y, Yu J, Guo J. MicroRNAs as Potential Biomarkers of Insecticide Exposure: A Review. Chem Res Toxicol 2019;32:2169-81. [PMID: 31625722 DOI: 10.1021/acs.chemrestox.9b00236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
463 Shen J, Wang A, Wang Q, Gurvich I, Siegel AB, Remotti H, Santella RM. Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiol Biomarkers Prev. 2013;22:2364-2373. [PMID: 24127413 DOI: 10.1158/1055-9965.epi-13-0237] [Cited by in Crossref: 72] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
464 Ventura L, Gnetti L, Rossi M, Tiseo M, Giordano G, Corradi M, Silva M, Milanese G, Minari R, Leonetti A, Cattadori S, Ampollini L, Carbognani P, Mozzoni P. The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios. Mol Biol Rep 2021;48:3485-94. [PMID: 33856606 DOI: 10.1007/s11033-021-06322-z] [Reference Citation Analysis]
465 Xi JJ. MicroRNAs in Cancer. Cancer Treat Res. 2013;158:119-137. [PMID: 24222356 DOI: 10.1007/978-3-642-31659-3_5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
466 Song J, Ouyang Y, Che J, Li X, Zhao Y, Yang K, Zhao X, Chen Y, Fan C, Yuan W. Potential Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases. Front Immunol 2017;8:56. [PMID: 28261196 DOI: 10.3389/fimmu.2017.00056] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 14.3] [Reference Citation Analysis]
467 Kim HS, Shen Q, Nam SW. Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis. J Korean Med Sci 2015;30:1375-80. [PMID: 26425032 DOI: 10.3346/jkms.2015.30.10.1375] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
468 Elemeery MN. Micro-RNA in Hepatocellular Carcinoma - Related Hepatitis C Virus Patients in Correlation to Disease Progression. In: Shahid I, editor. Hepatitis C - From Infection to Cure. InTech; 2018. [DOI: 10.5772/intechopen.76209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
469 Anestopoulos I, Voulgaridou GP, Georgakilas AG, Franco R, Pappa A, Panayiotidis MI. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103-119. [PMID: 25205159 DOI: 10.1016/j.pharmthera.2014.09.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
470 Meng F, Glaser SS, Francis H, Yang F, Han Y, Stokes A, Staloch D, McCarra J, Liu J, Venter J, Zhao H, Liu X, Francis T, Swendsen S, Liu CG, Tsukamoto H, Alpini G. Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol. 2012;181:804-817. [PMID: 22841474 DOI: 10.1016/j.ajpath.2012.06.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 10.8] [Reference Citation Analysis]
471 Sanchez-mejias A, Kwon J, Chew XH, Siemens A, Sohn HS, Jing G, Zhang B, Yang H, Tay Y. A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer: SOCS5/miR-18/miR-25 axis promotes tumorigenesis. Int J Cancer 2019;144:311-21. [DOI: 10.1002/ijc.31857] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
472 Huang S, Xie Y, Yang P, Chen P, Zhang L. HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. PLoS One. 2014;9:e81730. [PMID: 24416131 DOI: 10.1371/journal.pone.0081730] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
473 Mani SKK, Yan B, Cui Z, Sun J, Utturkar S, Foca A, Fares N, Durantel D, Lanman N, Merle P, Kazemian M, Andrisani O. Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma. Theranostics 2020;10:10957-72. [PMID: 33042264 DOI: 10.7150/thno.49629] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
474 Shi DM, Bian XY, Qin CD, Wu WZ. miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway. Onco Targets Ther 2018;11:571-85. [PMID: 29416358 DOI: 10.2147/OTT.S152611] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
475 Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. neo 2012;60:135-42. [DOI: 10.4149/neo_2013_018] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 8.3] [Reference Citation Analysis]
476 Xu X, Ye Q. Regulation of viral oncogenesis by microRNAs. Mol Cell Oncol 2014;1:e29910. [PMID: 27308317 DOI: 10.4161/mco.29910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
477 Cairo S, Wang Y, de Reyniès A, Duroure K, Dahan J, Redon MJ, Fabre M, McClelland M, Wang XW, Croce CM, Buendia MA. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A 2010;107:20471-6. [PMID: 21059911 DOI: 10.1073/pnas.1009009107] [Cited by in Crossref: 136] [Cited by in F6Publishing: 134] [Article Influence: 12.4] [Reference Citation Analysis]
478 Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia 2013;56:1971-9. [PMID: 23756832 DOI: 10.1007/s00125-013-2950-9] [Cited by in Crossref: 117] [Cited by in F6Publishing: 102] [Article Influence: 14.6] [Reference Citation Analysis]
479 Xu G, Yang F, Ding CL, Wang J, Zhao P, Wang W, Ren H. MiR-221 accentuates IFN׳s anti-HCV effect by downregulating SOCS1 and SOCS3. Virology 2014;462-463:343-50. [PMID: 25019494 DOI: 10.1016/j.virol.2014.06.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
480 Nicolaidou V, Koufaris C. MicroRNA responses to environmental liver carcinogens: Biological and clinical significance. Clin Chim Acta 2015;445:25-33. [PMID: 25773117 DOI: 10.1016/j.cca.2015.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
481 Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42. [DOI: 10.1002/mc.20712] [Cited by in Crossref: 379] [Cited by in F6Publishing: 365] [Article Influence: 34.5] [Reference Citation Analysis]
482 Lin YC, Chen TH, Huang YM, Wei PL, Lin JC. Involvement of microRNA in Solid Cancer: Role and Regulatory Mechanisms. Biomedicines 2021;9:343. [PMID: 33805515 DOI: 10.3390/biomedicines9040343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
483 Brase JC, Wuttig D, Kuner R, Sültmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9:306. [PMID: 21110877 DOI: 10.1186/1476-4598-9-306;] [Reference Citation Analysis]
484 Britto FA, Dumas K, Giorgetti-Peraldi S, Ollendorff V, Favier FB. Is REDD1 a metabolic double agent? Lessons from physiology and pathology. Am J Physiol Cell Physiol 2020;319:C807-24. [PMID: 32877205 DOI: 10.1152/ajpcell.00340.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
485 Wirsing A, Senkel S, Klein-Hitpass L, Ryffel GU. A systematic analysis of the 3’UTR of HNF4A mRNA reveals an interplay of regulatory elements including miRNA target sites. PLoS One. 2011;6:e27438. [PMID: 22140441 DOI: 10.1371/journal.pone.0027438] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
486 Yang J, Han S, Huang W, Chen T, Liu Y, Pan S, Li S. A meta-analysis of microRNA expression in liver cancer. PLoS One 2014;9:e114533. [PMID: 25490558 DOI: 10.1371/journal.pone.0114533] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
487 Yoon JS, Kim G, Lee YR, Park SY, Tak WY, Kweon YO, Park JG, Lee HW, Han YS, Ha HT, Chun JM, Jang SY, Hur K. Clinical significance of microRNA-21 expression in disease progression of patients with hepatocellular carcinoma. Biomark Med 2018;12:1105-14. [PMID: 30191729 DOI: 10.2217/bmm-2018-0096] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
488 Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol. 2018;15:137-151. [PMID: 29317776 DOI: 10.1038/nrgastro.2017.169] [Cited by in Crossref: 157] [Cited by in F6Publishing: 153] [Article Influence: 52.3] [Reference Citation Analysis]
489 Shibata C, Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Koike K. Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Molecular and Cellular Therapies. 2013;1:5. [PMID: 26056570 DOI: 10.1186/2052-8426-1-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
490 Zhang Y, Huang B, Wang HY, Chang A, Zheng XFS. Emerging Role of MicroRNAs in mTOR Signaling. Cell Mol Life Sci 2017;74:2613-25. [PMID: 28238105 DOI: 10.1007/s00018-017-2485-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
491 Murata A, Mori Y, Di Y, Sugai A, Das B, Takashima Y, Nakatani K. Small Molecule-Induced Dimerization of Hairpin RNA Interfered with the Dicer Cleavage Reaction. Biochemistry 2021;60:245-9. [PMID: 33476116 DOI: 10.1021/acs.biochem.0c00920] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
492 Rieswijk L, Brauers KJJ, Coonen MLJ, van Breda SGJ, Jennen DGJ, Kleinjans JCS. Evaluating microRNA profiles reveals discriminative responses following genotoxic or non-genotoxic carcinogen exposure in primary mouse hepatocytes. Mutagenesis 2015;30:771-84. [DOI: 10.1093/mutage/gev036] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
493 Xu SH, Yang YL, Han SM, Wu ZH. MicroRNA-9 expression is a prognostic biomarker in patients with osteosarcoma. World J Surg Oncol 2014;12:195. [PMID: 24969351 DOI: 10.1186/1477-7819-12-195] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
494 Kim J, Jiang J, Badawi M, Schmittgen TD. miR-221 regulates CD44 in hepatocellular carcinoma through the PI3K-AKT-mTOR pathway. Biochem Biophys Res Commun 2017;487:709-15. [PMID: 28442344 DOI: 10.1016/j.bbrc.2017.04.121] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
495 Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther 2012;12:1221-39. [PMID: 22731874 DOI: 10.1517/14712598.2012.697149] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]